3,4-亚甲基二氧基甲基苯丙胺对大鼠心肌细胞Connexin43以及细胞内钙稳态的影响
|
摘要
【研究背景】
摇头丸，其主要成分为3,4-亚甲基二氧基甲基苯丙胺（MDMA），常见于夜总会、迪吧、歌厅以及各种狂欢聚会场合，使用者多为22岁左右的年轻人。国内外研究及临床数据证实MDMA除了神经毒性之外，还具有肝毒性和心血管毒性。MDMA急性中毒可导致显著的心血管功能异常，表现为心率增加，血压增高以及心肌耗氧量增加引起高血压、心律失常、心肌缺血甚至心衰。已知的研究数据表明，MDMA可通过神经递质途径产生间接的心血管毒性作用，而其氧化代谢产物可破坏细胞抗氧化防御系统诱导氧化应激从而引起心肌细胞损伤。虽然大量的证据表明MDMA能够导致心功能异常，但是其对于心肌细胞的直接毒性作用的机制却尚未探明，MDMA是否还具有其它的心肌毒性作用仍然是未知领域。
心肌缝隙连接已经被广泛证实在维持心肌的正常搏动节律中起到至关重要的作用。它能够保持心肌细胞间搏动电传导的致性和稳定性。缝隙连接蛋白的异常，包括蛋白含量，分布以及磷酸化状态的改变，都可导致致死性心律失常的发生。然而，到目前为止，尚未有研究针对MDMA诱发心律失常与心室肌细胞缝隙连接蛋白之间的关联。基于前期的理论和实验基础，我们在本课题中针对MDMA与心肌细胞缝隙连接蛋白的影响进行深入的研究，从而进步揭示MDMA直接诱导心肌毒性的分子毒理机制。
【目的】
1.观察MDMA急性中毒对大鼠心电功能的影响；
2.观察MDMA急性中毒对大鼠心肌细胞缝隙连接蛋白43的影响；
3.体外原代培养新生大鼠心室肌细胞并构建体外MDMA急性染毒模型，观察不同浓度MDMA急性染毒对于心室肌细胞CX43蛋白表达含量以及转录水平的影响；
4.观察不同浓度MDMA急性染毒对于体外培养新生大鼠心室肌细胞间连接蛋白43含量以及分布的影响；
5.观察不同浓度的MDMA急性染毒对体外培养新生大鼠心室肌细胞连接蛋白43磷酸化位点Ser368磷酸化状态的影响；
6.观察MDMA急性染毒对于体外培养心室肌细胞内钙振荡模式以及细胞内钙离子浓度的影响。
【实验方法】
1.将摇头丸片剂研磨、溶解，对获得的溶液进行酸-碱反提萃取法提取MDMA有效成分，并运用气相色谱-质谱联用系统对提取物进行成分以及纯度检验；
2.动物实验：将18只SPF级SD大鼠随机分为实验组和对照组。实验组大鼠腹腔注射20mg/kg MDMA后实时记录其心电图以及心率变化。对照组则给予腹腔注射无菌生理盐水后记录其心电图以及心率变化。所有大鼠在24小时后采用颈椎脱臼法处死，迅速剪取心室部分并用生理盐水冲洗干净，多聚甲醛固定、石蜡包埋并制作切片。利用H&E染色观察心肌细胞形态学变化。利用免疫组织化学法对心室肌细胞中连接蛋白43进行定量分析，并观察其分布情况。
3.体外实验：选取0天或1天SPF级新生大鼠，消毒后迅速剪取心脏心室部分，利用混合组织消化液分步消化结合差速贴壁法获得纯化的心室肌细胞，置于培养箱中培养。于培养第6天，加入含有10、100、1000μM浓度的MDMA的无血清培养基进行急性染毒1小时，建立MDMA急性染毒体外模型。提取心室肌细胞总膜蛋白，利用蛋白免疫印迹法检测心室肌细胞中总连接蛋白43的表达含量的变化。同时提取细胞总RNA，利用荧光实时定量PCR法检测连接蛋白43mRNA（GJA1）表达含量的变化。
4.利用免疫荧光法检测不同浓度（10、100、1000μM）的MDMA染毒的心室肌细胞缝隙连接处连接蛋白43的表达和分布改变。
5.向体外培养的心室肌细胞中加入1000μM MDMA急性染毒1小时后，提取实验组和对照组心室肌细胞总蛋白，利用Western Blot法检测连接蛋白43磷酸化位点Ser368的磷酸化状态的改变，并检测心室肌细胞中PKC的含量。利用Fluo-4标记钙离子，在激光共聚焦显微镜下观察MDMA急性染毒组和对照组新生大鼠心室肌细胞内钙振荡模式的变化以及细胞内钙浓度的改变。
【数据分析】所有结果采用平均值±标准差。组间比较采用双向方差分析法，两组比较采用非配对t检验法，p值小于0.05为有统计学差异。所有统计学分析采用SPSS13.0软件以及Graph prism医学统计软件。
【结果】
1.从摇头丸中提取的MDMA成分经质谱检验未见其它活性杂质，MDMA纯度高达95%。
2.心电图结果显示急性MDMA腹腔注射后大鼠出现明显的心电图异常，表现为QRS间期延长，波幅增强，并呈现不规则变化。实时心率检测显示，实验组大鼠心率发生显著改变，大鼠心率变化起伏不定，并表现为不规则波动。实验组大鼠平均心率呈下降趋势。
3.实验组大鼠心室肌细胞未见明显形态学改变，部分视野下可见心肌纤维萎缩，横纹消失，肌浆呈嗜酸性变性，散在局灶性空泡样变性。
4.实验组大鼠中有2只大鼠在注射MDMA后2小时内发生自发性死亡。免疫组织化学结果显示，实验组大鼠心肌细胞连接蛋白43表达含量显著下降。自发性死亡大鼠心肌细胞可见连接蛋白43分布异常，沿心肌细胞两侧长轴方向分布。
5.体外培养的新生大鼠心室肌细胞可见成片搏动。MDMA急性染毒组心肌细胞总连接蛋白43含量以及连接蛋白43mRNA表达均显著下降。免疫荧光检测见100、1000μM高浓度MDMA染毒可引起缝隙连接中连接蛋白43的含量下降及分布异常。MDMA还引起心肌细胞N-钙粘蛋白的表达显著下降。
6.高浓度MDMA可导致连接蛋白43磷酸化状态改变，表现为非磷酸化状态比例上升，同时可引起磷酸化位点Ser368的磷酸化水平增加，但却对心肌细胞内PKC含量未造成影响。高浓度MDMA同时还引起心肌细胞内钙振荡模式的改变和钙离子浓度的上升。
【结论】
1.动物实验证实MDMA可诱发大鼠心率改变以及心电异常，甚至猝死，这些毒性作用与其引起心肌细胞连接蛋白43表达含量下降有关。
2.体外实验表明MDMA可直接作用于心室肌细胞引起连接蛋白43基因转录水平以及蛋白表达显著下降，同时其引起心肌N-钙粘蛋白水平的下调与MDMA导致连接蛋白43的分布异常有关。
3. MDMA可诱发心室肌细胞内钙振荡模式的改变以及细胞内钙离子浓度的增加介导相应蛋白激酶的活性引起连接蛋白43磷酸化磷酸化位点Ser368磷酸化水平升高。
4.本研究首次证实了MDMA可破坏心肌细胞内钙稳态，影响心肌细胞连接蛋白43的表达、分布以及磷酸化状态，诱发心电功能障碍，从而导致心律失常的发生。这也是MDMA直接心肌毒性的潜在作用机制之。
BACKGROUND
3,4-methylenedioxymethamphetamine (MDMA), also known as ‘Ecstasy’, ispopular among the young adults around25years old in night clubs and rave parties.The research and clinical data have determined that MDMA can induce not onlyneurotoxicity but also hepatoxicity and cardiovascular toxicity. Acute MDMAadministration can cause markedly cardiovascular dysfunction, including heartbeatrate, blood pressure and myocardial oxygen consumption increase, which result inhypertension, cardiac arrhythmia, myocardial infarction and even heart failure or heartarrest. Previous studies show MDMA may induce cardiotoxicity through indirect ordirect ways. Alteration of monoaminergic systems via the neurotoxic actions ofMDMA has the potential to cause cardiovascular changes. The oxidative metabolismof MDMA can also cause the oxidative stress in myocardial cells. Although plenty ofevidences have demonstrated that MDMA induce cardiac function disorder, the directeffect on the cardiomyocytes is still unclear. Whether MDMA has any othercardiotoxicity mechanisms is still unknown.
Myocardial gap junctions are widely known to play a significant role in thevelocity and the safety of impulse propagation in cardiac tissue, maintaining thenormal cardiac rhythm. Changes in gap junction proteins, including proteinexpression, distribution and phosphorylation status, may lead to fetal cardiacarrhythmia. However, there is no previous study focuses on the relationship betweenMDMA-induced arrhythmia and myocardial gap junctions alterations. Therefore,based on previous research findings, we firstly investigated the effect of MDMA onmyocardial gap junction proteins in this study. The results will further disclose thedirect mechanism of MDMA-induced cardiotoxicity.
OBJECTIVE
1. To observe the effect on rat’s electro-cardiac function after a single dose MDMAacute administration;
2. To investigate the change of myocardial gap junction connexin43proteinexpressions induced by acute MDMA administration
3. To investigate the alteration of total connexin43expression and Cx43mRNA levelin the primary cultured neonatal rats’ ventricular myocytes exposed to differentconcentration of MDMA;
4. To observe the changes of the amount and the distribution of junctional connxin43in cultured ventricular myocytes treated with MDMA;
5. To investigate the changes of phosphorylation status in connexin43Ser368ofcultured cells after exposure to different concentrations of MDMA.
6. To test the changes of intracellular Ca~(2+)oscillation patterns and calciumconcentration during MDMA exposure to the cultured ventricular myocytes.
METHODS
1. Ecstasy tablets were grinded into powder and then added pure water to solve itcompletely. Extraction of MDMA was performed by acid-base reactions. Thecomponents and purity of product was analyzed by GC-MS methods.
2. In vivo study: a total of18male SD rats (SPF grade) were divided into two groupsrandomly. The rats in experimental group were administrated by20mg/kg MDMA i.p..Subsequently, ECG was detected and recorded by ECG detector. Rats treated withsaline were used as control group. All the rats were sacrificed24hours after druginjections. The heart tissues were taken and washed by saline, and then fixed in4%paraformaldehyde for48hours prior to paraffin embedded. Sections of heart tissueswere HE stained. Immunohistochemical staining was performed to investigate theexpression and distribution of connexin43proteins.
3. in vitro study: newborn rats were sterilized and anesthetized. Cardiac ventricular was excised and shredded into tissue fragments. Step-wise digestion and90minutesdifferential adhesion were performed in order to enrich the culture with ventricularmyocytes. The cells were incubation in5%CO2at37. At the6thday, cultured cellswere added into10,100,1000μM MDMA with serum-free culture medium andincubated at37for1hour in order to establish MDMA intoxication models.Total membrane proteins of ventricular myocytes were extracted by using BioVisionprotein kit. Western blot was applied to test the change of total connexin43expressions. In addition, total RNA was extracted and the mRNA level of connexin43was quantitatively analyzed by application of Real time qPCR associated with2-(Δ(ΔCt))method.
4. The junctional connexin43in cultured cells exposed to MDMA (10,100,1000μM)were investigated by immunofluorescent staining in order to see the change of Cx43level and distribution.
5.1000μM MDMAwith serum-free culture medium was added onto the cultured cellsand incubated for1hour. Western blot was applied in order to test the alteration ofphosphorylation status in specific phosphorylated site Ser368of connexin43, as wellas the amount of PKCalpha. Besides, the intracellular calcium was label by Fluo-4and observed under confocal laser scanning microscope. The change of Ca~(2+)oscillation patterns and the intracellular Ca~(2+)concentration induced by MDMA weretest.
STATISTICAL ANALYSIS
Results are shown as mean±SEM, multiple comparisons between groups wereanalyzed by the two-way ANOVA. For two group comparisons, unpaired Student’st-test was used. A value of p<0.05was considered significant. All the statisticalanalysis were performed by using Graph prism software.
RESULTS
1. MDMA which was extracted from Ecstasy tablets were determined that no other pharmacological active components existed. The purity of extraction was95%.
2. Abnormal ECG findings were observed in experimental rats after a single doseMDMA acute administration, which was characterized by prolonged QRS duration,enhanced amplitudes associated with irregular changes. The heart rates of rats treatedwith MDMA showed significant changes with time. The average heart rate ofexperimental rats was significant decreased compared to control group.
3. H&E staining showed unremarkable morphological findings. Atrophy, eosinophilicdegeneration, myocytolysis and vacuolization were seen in the rats after MDMAadministration.
4. Two rats of experimental group died suddenly nearly2hours after MDMAinjection. IHC results showed the expression of connexin43was significantlydecreased in MDMA-treated rats compared to controls. In addition, it was observed indead rats that distributions of Cx43were strewn in longitudinally orientated arraysalong the lateral interfaces instead of confining to the sites of intercalated disks.
5. In vitro study, significant decrease in total connexin43expression was found inMDMA-treated cultured cells associated with the obvious down-regulation of Cx43mRNA level. Immunofluorescent detection showed high concentration of MDMA ledto significant decrease of junctional connexin43and MDMA caused parallel reductionof N-cadherin level in cultured ventricular myocytes.
6. high concentration of MDMA (1000μM) also increased the non-phosphorylatedconnexin43, and induced the increase of phosphorylated Cx43at site Ser368. Therewas no significant difference in PKCalpha between MDMA-treated and controlgroups. However, intracellular Ca~(2+)oscillation patterns alterations and increase ofintracellular Ca~(2+)concentrations were found induced by high concentration ofMDMA.
CONCLUSIONS
1. A single dose of MDMA acute administration can cause reduction of myocardialconnexin43and induce changes in heart rate and ECG patterns of rats.
2. MDMA directly affects the cardiomyocytes and results in decrease of totalconnexin43and abnormal connexin43distribution which may be related to thereduction of N-cadherin induced by MDMA.
3. MDMA induces the changes in intracellular Ca~(2+)oscillation patterns and increaseof Ca~(2+)concentration, which may activate related protein kinases and up-regulate thephosphorylated Cx43Ser368.
4. Our findings provide first evidence of MDMA-mediated changes in cardiac gapjunctions that may underlie MDMA-induced cardiac arrhythmia.
摇头丸，其主要成分为3,4-亚甲基二氧基甲基苯丙胺（MDMA），常见于夜总会、迪吧、歌厅以及各种狂欢聚会场合，使用者多为22岁左右的年轻人。国内外研究及临床数据证实MDMA除了神经毒性之外，还具有肝毒性和心血管毒性。MDMA急性中毒可导致显著的心血管功能异常，表现为心率增加，血压增高以及心肌耗氧量增加引起高血压、心律失常、心肌缺血甚至心衰。已知的研究数据表明，MDMA可通过神经递质途径产生间接的心血管毒性作用，而其氧化代谢产物可破坏细胞抗氧化防御系统诱导氧化应激从而引起心肌细胞损伤。虽然大量的证据表明MDMA能够导致心功能异常，但是其对于心肌细胞的直接毒性作用的机制却尚未探明，MDMA是否还具有其它的心肌毒性作用仍然是未知领域。
心肌缝隙连接已经被广泛证实在维持心肌的正常搏动节律中起到至关重要的作用。它能够保持心肌细胞间搏动电传导的致性和稳定性。缝隙连接蛋白的异常，包括蛋白含量，分布以及磷酸化状态的改变，都可导致致死性心律失常的发生。然而，到目前为止，尚未有研究针对MDMA诱发心律失常与心室肌细胞缝隙连接蛋白之间的关联。基于前期的理论和实验基础，我们在本课题中针对MDMA与心肌细胞缝隙连接蛋白的影响进行深入的研究，从而进步揭示MDMA直接诱导心肌毒性的分子毒理机制。
【目的】
1.观察MDMA急性中毒对大鼠心电功能的影响；
2.观察MDMA急性中毒对大鼠心肌细胞缝隙连接蛋白43的影响；
3.体外原代培养新生大鼠心室肌细胞并构建体外MDMA急性染毒模型，观察不同浓度MDMA急性染毒对于心室肌细胞CX43蛋白表达含量以及转录水平的影响；
4.观察不同浓度MDMA急性染毒对于体外培养新生大鼠心室肌细胞间连接蛋白43含量以及分布的影响；
5.观察不同浓度的MDMA急性染毒对体外培养新生大鼠心室肌细胞连接蛋白43磷酸化位点Ser368磷酸化状态的影响；
6.观察MDMA急性染毒对于体外培养心室肌细胞内钙振荡模式以及细胞内钙离子浓度的影响。
【实验方法】
1.将摇头丸片剂研磨、溶解，对获得的溶液进行酸-碱反提萃取法提取MDMA有效成分，并运用气相色谱-质谱联用系统对提取物进行成分以及纯度检验；
2.动物实验：将18只SPF级SD大鼠随机分为实验组和对照组。实验组大鼠腹腔注射20mg/kg MDMA后实时记录其心电图以及心率变化。对照组则给予腹腔注射无菌生理盐水后记录其心电图以及心率变化。所有大鼠在24小时后采用颈椎脱臼法处死，迅速剪取心室部分并用生理盐水冲洗干净，多聚甲醛固定、石蜡包埋并制作切片。利用H&E染色观察心肌细胞形态学变化。利用免疫组织化学法对心室肌细胞中连接蛋白43进行定量分析，并观察其分布情况。
3.体外实验：选取0天或1天SPF级新生大鼠，消毒后迅速剪取心脏心室部分，利用混合组织消化液分步消化结合差速贴壁法获得纯化的心室肌细胞，置于培养箱中培养。于培养第6天，加入含有10、100、1000μM浓度的MDMA的无血清培养基进行急性染毒1小时，建立MDMA急性染毒体外模型。提取心室肌细胞总膜蛋白，利用蛋白免疫印迹法检测心室肌细胞中总连接蛋白43的表达含量的变化。同时提取细胞总RNA，利用荧光实时定量PCR法检测连接蛋白43mRNA（GJA1）表达含量的变化。
4.利用免疫荧光法检测不同浓度（10、100、1000μM）的MDMA染毒的心室肌细胞缝隙连接处连接蛋白43的表达和分布改变。
5.向体外培养的心室肌细胞中加入1000μM MDMA急性染毒1小时后，提取实验组和对照组心室肌细胞总蛋白，利用Western Blot法检测连接蛋白43磷酸化位点Ser368的磷酸化状态的改变，并检测心室肌细胞中PKC的含量。利用Fluo-4标记钙离子，在激光共聚焦显微镜下观察MDMA急性染毒组和对照组新生大鼠心室肌细胞内钙振荡模式的变化以及细胞内钙浓度的改变。
【数据分析】所有结果采用平均值±标准差。组间比较采用双向方差分析法，两组比较采用非配对t检验法，p值小于0.05为有统计学差异。所有统计学分析采用SPSS13.0软件以及Graph prism医学统计软件。
【结果】
1.从摇头丸中提取的MDMA成分经质谱检验未见其它活性杂质，MDMA纯度高达95%。
2.心电图结果显示急性MDMA腹腔注射后大鼠出现明显的心电图异常，表现为QRS间期延长，波幅增强，并呈现不规则变化。实时心率检测显示，实验组大鼠心率发生显著改变，大鼠心率变化起伏不定，并表现为不规则波动。实验组大鼠平均心率呈下降趋势。
3.实验组大鼠心室肌细胞未见明显形态学改变，部分视野下可见心肌纤维萎缩，横纹消失，肌浆呈嗜酸性变性，散在局灶性空泡样变性。
4.实验组大鼠中有2只大鼠在注射MDMA后2小时内发生自发性死亡。免疫组织化学结果显示，实验组大鼠心肌细胞连接蛋白43表达含量显著下降。自发性死亡大鼠心肌细胞可见连接蛋白43分布异常，沿心肌细胞两侧长轴方向分布。
5.体外培养的新生大鼠心室肌细胞可见成片搏动。MDMA急性染毒组心肌细胞总连接蛋白43含量以及连接蛋白43mRNA表达均显著下降。免疫荧光检测见100、1000μM高浓度MDMA染毒可引起缝隙连接中连接蛋白43的含量下降及分布异常。MDMA还引起心肌细胞N-钙粘蛋白的表达显著下降。
6.高浓度MDMA可导致连接蛋白43磷酸化状态改变，表现为非磷酸化状态比例上升，同时可引起磷酸化位点Ser368的磷酸化水平增加，但却对心肌细胞内PKC含量未造成影响。高浓度MDMA同时还引起心肌细胞内钙振荡模式的改变和钙离子浓度的上升。
【结论】
1.动物实验证实MDMA可诱发大鼠心率改变以及心电异常，甚至猝死，这些毒性作用与其引起心肌细胞连接蛋白43表达含量下降有关。
2.体外实验表明MDMA可直接作用于心室肌细胞引起连接蛋白43基因转录水平以及蛋白表达显著下降，同时其引起心肌N-钙粘蛋白水平的下调与MDMA导致连接蛋白43的分布异常有关。
3. MDMA可诱发心室肌细胞内钙振荡模式的改变以及细胞内钙离子浓度的增加介导相应蛋白激酶的活性引起连接蛋白43磷酸化磷酸化位点Ser368磷酸化水平升高。
4.本研究首次证实了MDMA可破坏心肌细胞内钙稳态，影响心肌细胞连接蛋白43的表达、分布以及磷酸化状态，诱发心电功能障碍，从而导致心律失常的发生。这也是MDMA直接心肌毒性的潜在作用机制之。
BACKGROUND
3,4-methylenedioxymethamphetamine (MDMA), also known as ‘Ecstasy’, ispopular among the young adults around25years old in night clubs and rave parties.The research and clinical data have determined that MDMA can induce not onlyneurotoxicity but also hepatoxicity and cardiovascular toxicity. Acute MDMAadministration can cause markedly cardiovascular dysfunction, including heartbeatrate, blood pressure and myocardial oxygen consumption increase, which result inhypertension, cardiac arrhythmia, myocardial infarction and even heart failure or heartarrest. Previous studies show MDMA may induce cardiotoxicity through indirect ordirect ways. Alteration of monoaminergic systems via the neurotoxic actions ofMDMA has the potential to cause cardiovascular changes. The oxidative metabolismof MDMA can also cause the oxidative stress in myocardial cells. Although plenty ofevidences have demonstrated that MDMA induce cardiac function disorder, the directeffect on the cardiomyocytes is still unclear. Whether MDMA has any othercardiotoxicity mechanisms is still unknown.
Myocardial gap junctions are widely known to play a significant role in thevelocity and the safety of impulse propagation in cardiac tissue, maintaining thenormal cardiac rhythm. Changes in gap junction proteins, including proteinexpression, distribution and phosphorylation status, may lead to fetal cardiacarrhythmia. However, there is no previous study focuses on the relationship betweenMDMA-induced arrhythmia and myocardial gap junctions alterations. Therefore,based on previous research findings, we firstly investigated the effect of MDMA onmyocardial gap junction proteins in this study. The results will further disclose thedirect mechanism of MDMA-induced cardiotoxicity.
OBJECTIVE
1. To observe the effect on rat’s electro-cardiac function after a single dose MDMAacute administration;
2. To investigate the change of myocardial gap junction connexin43proteinexpressions induced by acute MDMA administration
3. To investigate the alteration of total connexin43expression and Cx43mRNA levelin the primary cultured neonatal rats’ ventricular myocytes exposed to differentconcentration of MDMA;
4. To observe the changes of the amount and the distribution of junctional connxin43in cultured ventricular myocytes treated with MDMA;
5. To investigate the changes of phosphorylation status in connexin43Ser368ofcultured cells after exposure to different concentrations of MDMA.
6. To test the changes of intracellular Ca~(2+)oscillation patterns and calciumconcentration during MDMA exposure to the cultured ventricular myocytes.
METHODS
1. Ecstasy tablets were grinded into powder and then added pure water to solve itcompletely. Extraction of MDMA was performed by acid-base reactions. Thecomponents and purity of product was analyzed by GC-MS methods.
2. In vivo study: a total of18male SD rats (SPF grade) were divided into two groupsrandomly. The rats in experimental group were administrated by20mg/kg MDMA i.p..Subsequently, ECG was detected and recorded by ECG detector. Rats treated withsaline were used as control group. All the rats were sacrificed24hours after druginjections. The heart tissues were taken and washed by saline, and then fixed in4%paraformaldehyde for48hours prior to paraffin embedded. Sections of heart tissueswere HE stained. Immunohistochemical staining was performed to investigate theexpression and distribution of connexin43proteins.
3. in vitro study: newborn rats were sterilized and anesthetized. Cardiac ventricular was excised and shredded into tissue fragments. Step-wise digestion and90minutesdifferential adhesion were performed in order to enrich the culture with ventricularmyocytes. The cells were incubation in5%CO2at37. At the6thday, cultured cellswere added into10,100,1000μM MDMA with serum-free culture medium andincubated at37for1hour in order to establish MDMA intoxication models.Total membrane proteins of ventricular myocytes were extracted by using BioVisionprotein kit. Western blot was applied to test the change of total connexin43expressions. In addition, total RNA was extracted and the mRNA level of connexin43was quantitatively analyzed by application of Real time qPCR associated with2-(Δ(ΔCt))method.
4. The junctional connexin43in cultured cells exposed to MDMA (10,100,1000μM)were investigated by immunofluorescent staining in order to see the change of Cx43level and distribution.
5.1000μM MDMAwith serum-free culture medium was added onto the cultured cellsand incubated for1hour. Western blot was applied in order to test the alteration ofphosphorylation status in specific phosphorylated site Ser368of connexin43, as wellas the amount of PKCalpha. Besides, the intracellular calcium was label by Fluo-4and observed under confocal laser scanning microscope. The change of Ca~(2+)oscillation patterns and the intracellular Ca~(2+)concentration induced by MDMA weretest.
STATISTICAL ANALYSIS
Results are shown as mean±SEM, multiple comparisons between groups wereanalyzed by the two-way ANOVA. For two group comparisons, unpaired Student’st-test was used. A value of p<0.05was considered significant. All the statisticalanalysis were performed by using Graph prism software.
RESULTS
1. MDMA which was extracted from Ecstasy tablets were determined that no other pharmacological active components existed. The purity of extraction was95%.
2. Abnormal ECG findings were observed in experimental rats after a single doseMDMA acute administration, which was characterized by prolonged QRS duration,enhanced amplitudes associated with irregular changes. The heart rates of rats treatedwith MDMA showed significant changes with time. The average heart rate ofexperimental rats was significant decreased compared to control group.
3. H&E staining showed unremarkable morphological findings. Atrophy, eosinophilicdegeneration, myocytolysis and vacuolization were seen in the rats after MDMAadministration.
4. Two rats of experimental group died suddenly nearly2hours after MDMAinjection. IHC results showed the expression of connexin43was significantlydecreased in MDMA-treated rats compared to controls. In addition, it was observed indead rats that distributions of Cx43were strewn in longitudinally orientated arraysalong the lateral interfaces instead of confining to the sites of intercalated disks.
5. In vitro study, significant decrease in total connexin43expression was found inMDMA-treated cultured cells associated with the obvious down-regulation of Cx43mRNA level. Immunofluorescent detection showed high concentration of MDMA ledto significant decrease of junctional connexin43and MDMA caused parallel reductionof N-cadherin level in cultured ventricular myocytes.
6. high concentration of MDMA (1000μM) also increased the non-phosphorylatedconnexin43, and induced the increase of phosphorylated Cx43at site Ser368. Therewas no significant difference in PKCalpha between MDMA-treated and controlgroups. However, intracellular Ca~(2+)oscillation patterns alterations and increase ofintracellular Ca~(2+)concentrations were found induced by high concentration ofMDMA.
CONCLUSIONS
1. A single dose of MDMA acute administration can cause reduction of myocardialconnexin43and induce changes in heart rate and ECG patterns of rats.
2. MDMA directly affects the cardiomyocytes and results in decrease of totalconnexin43and abnormal connexin43distribution which may be related to thereduction of N-cadherin induced by MDMA.
3. MDMA induces the changes in intracellular Ca~(2+)oscillation patterns and increaseof Ca~(2+)concentration, which may activate related protein kinases and up-regulate thephosphorylated Cx43Ser368.
4. Our findings provide first evidence of MDMA-mediated changes in cardiac gapjunctions that may underlie MDMA-induced cardiac arrhythmia.
引文
[1] Berger UV, Gu XF, Azmitia EC. The substituted amphetamines3,4-methylenedioxymethamphetamine, methamphetamine,p-chloroamphetamine and fenfluramine induce5-hydroxytryptamine releasevia a common mechanism blocked by fluoxetine and cocaine [J]. Eur JPharmacol,1992,215(2-3):153-160.
[2] Crespi D, Mennini T, Gobbi M. Carrier-dependent and Ca(2+)-dependent5-HT and dopamine release induced by (+)-amphetamine,3,4-methylendioxymethamphetamine, p-chloroamphetamine and(+)-fenfluramine [J]. Br J Pharmacol,1997,121(8):1735-1743.
[3] Vollenweider FX, Gamma A, Liechti M,et al. Psychological andcardiovascular effects and short-term sequelae of MDMA ("ecstasy") inMDMA-naive healthy volunteers [J]. Neuropsychopharmacology,1998,19(4):241-251.
[4] Cohen RS, Cocores J. Neuropsychiatric manifestations following the use of3,4-methylenedioxymethamphetamine (MDMA:"Ecstasy")[J]. ProgNeuropsychopharmacol Biol Psychiatry,1997,21(4):727-734.
[5] Kolbrich EA, Goodwin RS, Gorelick DA,et al. Physiological and subjectiveresponses to controlled oral3,4-methylenedioxymethamphetamineadministration [J]. J Clin Psychopharmacol,2008,28(4):432-440.
[6]孙毅,徐本树,王志强,et al.250例苯丙胺类摇头丸（MDMA）滥用人群分析[J].中国药物滥用防治杂志,2004,10(5):3.
[7] Crean RD, Davis SA, Von Huben SN,et al. Effects of(+/-)3,4-methylenedioxymethamphetamine,(+/-)3,4-methylenedioxyamphetamine and methamphetamine on temperatureand activity in rhesus macaques [J]. Neuroscience,2006,142(2):515-525.
[8] Hall AP, Henry JA. Acute toxic effects of 'Ecstasy'(MDMA) and relatedcompounds: overview of pathophysiology and clinical management [J]. Br JAnaesth,2006,96(6):678-685.
[9] Sprague JE, Preston AS, Leifheit M,et al. Hippocampal serotonergic damageinduced by MDMA (ecstasy): effects on spatial learning [J]. Physiol Behav,2003,79(2):281-287.
[10] Badon LA, Hicks A, Lord K,et al. Changes in cardiovascular responsivenessand cardiotoxicity elicited during binge administration of Ecstasy [J]. JPharmacol Exp Ther,2002,302(3):898-907.
[11] Gesi M, Lenzi P, Soldani P,et al. Morphological effects in the mousemyocardium after methylenedioxymethamphetamine administration combinedwith loud noise exposure [J]. Anat Rec,2002,267(1):37-46.
[12] Gesi M, Soldani P, Lenzi P,et al. Ecstasy during loud noise exposure inducesdramatic ultrastructural changes in the heart [J]. Pharmacol Toxicol,2002,91(1):29-33.
[13] Kaye S, Darke S, Duflou J. Methylenedioxymethamphetamine(MDMA)-related fatalities in Australia: demographics, circumstances,toxicology and major organ pathology [J]. Drug Alcohol Depend,2009,104(3):254-261.
[14] Yeo KK, Wijetunga M, Ito H,et al. The association of methamphetamine useand cardiomyopathy in young patients [J]. Am J Med,2007,120(2):165-171.
[15] Mas M, Farre M, de la Torre R,et al. Cardiovascular and neuroendocrineeffects and pharmacokinetics of3,4-methylenedioxymethamphetamine inhumans [J]. J Pharmacol Exp Ther,1999,290(1):136-145.
[16] Madhok A, Boxer R, Chowdhury D. Atrial fibrillation in an adolescent--theagony of ecstasy [J]. Pediatr Emerg Care,2003,19(5):348-349.
[17] Diffley M, Armenian P, Gerona R,et al. Catecholaminergic polymorphicventricular tachycardia found in an adolescent after amethylenedioxymethamphetamine and marijuana-induced cardiac arrest [J].Crit Care Med,2012,40(7):2223-2226.
[18] O'Cain PA, Hletko SB, Ogden BA,et al. Cardiovascular and sympatheticresponses and reflex changes elicited by MDMA [J]. Physiol Behav,2000,70(1-2):141-148.
[19] Bolton JL, Trush MA, Penning TM,et al. Role of quinones in toxicology [J].Chem Res Toxicol,2000,13(3):135-160.
[20] Carvalho M, Remiao F, Milhazes N,et al. Metabolism is required for theexpression of ecstasy-induced cardiotoxicity in vitro [J]. Chem Res Toxicol,2004,17(5):623-632.
[21] Carvalho M, Hawksworth G, Milhazes N,et al. Role of metabolites in MDMA(ecstasy)-induced nephrotoxicity: an in vitro study using rat and human renalproximal tubular cells [J]. Arch Toxicol,2002,76(10):581-588.
[22] Saez JC, Berthoud VM, Branes MC,et al. Plasma membrane channels formedby connexins: their regulation and functions [J]. Physiol Rev,2003,83(4):1359-1400.
[23] Elfgang C, Eckert R, Lichtenberg-Frate H,et al. Specific permeability andselective formation of gap junction channels in connexin-transfected HeLacells [J]. J Cell Biol,1995,129(3):805-817.
[24] Wilkins AS. Gap junction-mediated intercellular signalling in health anddisease [J]. Bioessays,1998,20(8):686-688.
[25] Dhein S. Gap junction channels in the cardiovascular system: pharmacologicaland physiological modulation [J]. Trends Pharmacol Sci,1998,19(6):229-241.
[26] Urschel S, Hoher T, Schubert T,et al. Protein kinase A-mediatedphosphorylation of connexin36in mouse retina results in decreased gapjunctional communication between AII amacrine cells [J]. J Biol Chem,2006,281(44):33163-33171.
[27] Tribulova N, Knezl V, Okruhlicova L,et al. Myocardial gap junctions: targetsfor novel approaches in the prevention of life-threatening cardiac arrhythmias[J]. Physiol Res,2008,57Suppl2(S1-S13.
[28] Solan JL, Lampe PD. Connexin43phosphorylation: structural changes andbiological effects [J]. Biochem J,2009,419(2):261-272.
[29] Delmar M, Makita N. Cardiac connexins, mutations and arrhythmias [J]. CurrOpin Cardiol,2012,27(3):236-241.
[30] Zhang SW, Liu Y, Huang GZ,et al. Aconitine alters connexin43phosphorylation status and [Ca2+] oscillation patterns in cultured ventricularmyocytes of neonatal rats [J]. Toxicol In Vitro,2007,21(8):1476-1485.
[1] Freudenmann RW, Oxler F, Bernschneider-Reif S. The origin of MDMA(ecstasy) revisited: the true story reconstructed from the original documents [J].Addiction,2006,101(9):1241-1245.
[2] Pentney AR. An exploration of the history and controversies surroundingMDMA and MDA [J]. J Psychoactive Drugs,2001,33(3):213-221.
[3] Strote J, Lee JE, Wechsler H. Increasing MDMA use among college students:results of a national survey [J]. J Adolesc Health,2002,30(1):64-72.
[4]刘志民,周伟华,智连,et al.“摇头丸”滥用情况调查[J].中国心理卫生杂志,2000,14(5):1.
[5]卢金山,刘朝华,张锐,et al.武汉地区苯丙胺类兴奋剂滥用者的调查[J].中国药物滥用防治杂志,2008,14(1):2.
[6]刘铁桥,伟郝,王小平,et al.苯丙胺类兴奋剂(ATS)娱乐性使用情况及其人群特征[J].中国心理卫生杂志,2002,16(5):4.
[7] Carter JF, Titterton a E, Murray M,et al. Isotopic characterisation of3,4-methylenedioxyamphetamine and3,4-methylenedioxymethylamphetamine(ecstasy)[J]. Analyst,2002,127(6):830-833.
[8] Swist M, Wilamowski J, Parczewski A. Determination of synthesis method ofecstasy based on the basic impurities [J]. Forensic Sci Int,2005,152(2-3):175-184.
[9] Gimeno P, Besacier F, Bottex M,et al. A study of impurities in intermediatesand3,4-methylenedioxymethamphetamine (MDMA) samples produced viareductive amination routes [J]. Forensic Sci Int,2005,155(2-3):141-157.
[10] Puthaviriyakorn V, Siriviriyasomboon N, Phorachata J,et al. Identification ofimpurities and statistical classification of methamphetamine tablets (Ya-Ba)seized in Thailand [J]. Forensic Sci Int,2002,126(2):105-113.
[11] Gimeno P, Besacier F, Chaudron-Thozet H,et al. A contribution to thechemical profiling of3,4-methylenedioxymethamphetamine (MDMA) tablets[J]. Forensic Sci Int,2002,127(1-2):1-44.
[12] Rashed AM, Anderson RA, King LA. Solid-phase extraction for profiling ofecstasy tablets [J]. J Forensic Sci,2000,45(2):413-417.
[13] Inoue H, Kanamori T, Iwata YT,et al. Methamphetamine impurity profilingusing a0.32mm i.d. nonpolar capillary column [J]. Forensic Sci Int,2003,135(1):42-47.
[14]王虹,王军.“摇头丸”中主要成分检验[J].公安大学学报（自然科学版）,2003,33(1):3.
[15]叶青,成云飞,张祥民.摇头丸中氯胺酮和咖啡因的现场快速检测[J].化学研究与应用,2011,23(7):3.
[16] Milroy CM, Clark JC, Forrest AR. Pathology of deaths associated with"ecstasy" and "eve" misuse [J]. J Clin Pathol,1996,49(2):149-153.
[17] Baggott M, Heifets B, Jones RT,et al. Chemical analysis of ecstasy pills [J].JAMA,2000,284(17):2190.
[18] Freudenmann RW, Spitzer M. The Neuropsychopharmacology and Toxicologyof3,4-methylenedioxy-N-ethyl-amphetamine (MDEA)[J]. CNS Drug Rev,2004,10(2):89-116.
[19] Parrott AC. Is ecstasy MDMA? A review of the proportion of ecstasy tabletscontaining MDMA, their dosage levels, and the changing perceptions of purity[J]. Psychopharmacology (Berl),2004,173(3-4):234-241.
[20] Cole JC, Bailey M, Sumnall HR,et al. The content of ecstasy tablets:implications for the study of their long-term effects [J]. Addiction,2002,97(12):1531-1536.
[21]吴国萍,相秉仁.近红外光谱技术应用于摇头丸中MDMA、MA无损定量分析的研究[J].分析测试学报,2007,26(5):3.
[1] Greer G, Tolbert R. Subjective reports of the effects of MDMA in a clinicalsetting [J]. J Psychoactive Drugs,1986,18(4):319-327.
[2] Dowling GP, McDonough ET,3rd, Bost RO.'Eve' and 'Ecstasy'. A report offive deaths associated with the use of MDEA and MDMA [J]. JAMA,1987,257(12):1615-1617.
[3] Berger UV, Gu XF, Azmitia EC. The substituted amphetamines3,4-methylenedioxymethamphetamine, methamphetamine,p-chloroamphetamine and fenfluramine induce5-hydroxytryptamine releasevia a common mechanism blocked by fluoxetine and cocaine [J]. Eur JPharmacol,1992,215(2-3):153-160.
[4] Crespi D, Mennini T, Gobbi M. Carrier-dependent and Ca(2+)-dependent5-HT and dopamine release induced by (+)-amphetamine,3,4-methylendioxymethamphetamine, p-chloroamphetamine and(+)-fenfluramine [J]. Br J Pharmacol,1997,121(8):1735-1743.
[5] Han DD, Gu HH. Comparison of the monoamine transporters from human andmouse in their sensitivities to psychostimulant drugs [J]. BMC Pharmacol,2006,6(6.
[6] Vollenweider FX, Gamma A, Liechti M,et al. Psychological andcardiovascular effects and short-term sequelae of MDMA ("ecstasy") inMDMA-naive healthy volunteers [J]. Neuropsychopharmacology,1998,19(4):241-251.
[7] Cohen RS, Cocores J. Neuropsychiatric manifestations following the use of3,4-methylenedioxymethamphetamine (MDMA:"Ecstasy")[J]. ProgNeuropsychopharmacol Biol Psychiatry,1997,21(4):727-734.
[8] Kolbrich EA, Goodwin RS, Gorelick DA,et al. Physiological and subjectiveresponses to controlled oral3,4-methylenedioxymethamphetamineadministration [J]. J Clin Psychopharmacol,2008,28(4):432-440.
[9] Crean RD, Davis SA, Von Huben SN,et al. Effects of(+/-)3,4-methylenedioxymethamphetamine,(+/-)3,4-methylenedioxyamphetamine and methamphetamine on temperatureand activity in rhesus macaques [J]. Neuroscience,2006,142(2):515-525.
[10] Hall AP, Henry JA. Acute toxic effects of 'Ecstasy'(MDMA) and relatedcompounds: overview of pathophysiology and clinical management [J]. Br JAnaesth,2006,96(6):678-685.
[11] Sprague JE, Preston AS, Leifheit M,et al. Hippocampal serotonergic damageinduced by MDMA (ecstasy): effects on spatial learning [J]. Physiol Behav,2003,79(2):281-287.
[12] Badon LA, Hicks A, Lord K,et al. Changes in cardiovascular responsivenessand cardiotoxicity elicited during binge administration of Ecstasy [J]. JPharmacol Exp Ther,2002,302(3):898-907.
[13] Gesi M, Lenzi P, Soldani P,et al. Morphological effects in the mousemyocardium after methylenedioxymethamphetamine administration combinedwith loud noise exposure [J]. Anat Rec,2002,267(1):37-46.
[14] Gesi M, Soldani P, Lenzi P,et al. Ecstasy during loud noise exposure inducesdramatic ultrastructural changes in the heart [J]. Pharmacol Toxicol,2002,91(1):29-33.
[15] Mas M, Farre M, de la Torre R,et al. Cardiovascular and neuroendocrineeffects and pharmacokinetics of3,4-methylenedioxymethamphetamine inhumans [J]. J Pharmacol Exp Ther,1999,290(1):136-145.
[16] Madhok A, Boxer R, Chowdhury D. Atrial fibrillation in an adolescent--theagony of ecstasy [J]. Pediatr Emerg Care,2003,19(5):348-349.
[17] Diffley M, Armenian P, Gerona R,et al. Catecholaminergic polymorphicventricular tachycardia found in an adolescent after amethylenedioxymethamphetamine and marijuana-induced cardiac arrest [J].Crit Care Med,2012,40(7):2223-2226.
[18] Kaye S, Darke S, Duflou J. Methylenedioxymethamphetamine(MDMA)-related fatalities in Australia: demographics, circumstances,toxicology and major organ pathology [J]. Drug Alcohol Depend,2009,104(3):254-261.
[19] Yeo KK, Wijetunga M, Ito H,et al. The association of methamphetamine useand cardiomyopathy in young patients [J]. Am J Med,2007,120(2):165-171.
[20] O'Cain PA, Hletko SB, Ogden BA,et al. Cardiovascular and sympatheticresponses and reflex changes elicited by MDMA [J]. Physiol Behav,2000,70(1-2):141-148.
[21] Saez JC, Berthoud VM, Branes MC,et al. Plasma membrane channels formedby connexins: their regulation and functions [J]. Physiol Rev,2003,83(4):1359-1400.
[22] Elfgang C, Eckert R, Lichtenberg-Frate H,et al. Specific permeability andselective formation of gap junction channels in connexin-transfected HeLacells [J]. J Cell Biol,1995,129(3):805-817.
[23] Wilkins AS. Gap junction-mediated intercellular signalling in health anddisease [J]. Bioessays,1998,20(8):686-688.
[24] Dhein S. Gap junction channels in the cardiovascular system: pharmacologicaland physiological modulation [J]. Trends Pharmacol Sci,1998,19(6):229-241.
[25] Tribulova N, Knezl V, Okruhlicova L,et al. Myocardial gap junctions: targetsfor novel approaches in the prevention of life-threatening cardiac arrhythmias[J]. Physiol Res,2008,57Suppl2(S1-S13.
[26] Solan JL, Lampe PD. Connexin43phosphorylation: structural changes andbiological effects [J]. Biochem J,2009,419(2):261-272.
[27] Delmar M, Makita N. Cardiac connexins, mutations and arrhythmias [J]. CurrOpin Cardiol,2012,27(3):236-241.
[28] Cole JC, Sumnall HR. The pre-clinical behavioural pharmacology of3,4-methylenedioxymethamphetamine (MDMA)[J]. Neurosci Biobehav Rev,2003,27(3):199-217.
[29] Green AR, Mechan AO, Elliott JM,et al. The pharmacology and clinicalpharmacology of3,4-methylenedioxymethamphetamine (MDMA,"ecstasy")[J]. Pharmacol Rev,2003,55(3):463-508.
[30] Schifano F. A bitter pill. Overview of ecstasy (MDMA, MDA) relatedfatalities [J]. Psychopharmacology (Berl),2004,173(3-4):242-248.
[31] White CR, Seymour RS. Allometric scaling of mammalian metabolism [J]. JExp Biol,2005,208(Pt9):1611-1619.
[32] Winneke G, Lilienthal H. Extrapolation from animals to humans: scientificand regulatory aspects [J]. Toxicol Lett,1992,64-65Spec No(239-246.
[33] Baumann MH, Clark RD, Budzynski AG,et al. N-substituted piperazinesabused by humans mimic the molecular mechanism of3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy')[J].Neuropsychopharmacology,2005,30(3):550-560.
[34] Glennon RA, Higgs R. Investigation of MDMA-related agents in rats trainedto discriminate MDMA from saline [J]. Pharmacol Biochem Behav,1992,43(3):759-763.
[35] Oberlender R, Nichols DE. Drug discrimination studies with MDMA andamphetamine [J]. Psychopharmacology (Berl),1988,95(1):71-76.
[36] Poland RE, Lutchmansingh P, McCracken JT,et al. Abnormal ACTH andprolactin responses to fenfluramine in rats exposed to single and multipledoses of MDMA [J]. Psychopharmacology (Berl),1997,131(4):411-419.
[37] Baumann MH, Rothman RB. Neural and cardiac toxicities associated with3,4-methylenedioxymethamphetamine (MDMA)[J]. Int Rev Neurobiol,2009,88(257-296.
[38] Islam MN, Kuroki H, Hongcheng B,et al. Cardiac lesions and theirreversibility after long term administration of methamphetamine [J]. ForensicSci Int,1995,75(1):29-43.
[39] He SY, Matoba R, Fujitani N,et al. Cardiac muscle lesions associated withchronic administration of methamphetamine in rats [J]. Am J Forensic MedPathol,1996,17(2):155-162.
[40] Maeno Y, Iwasa M, Inoue H,et al. Direct effects of methamphetamine onhypertrophy and microtubules in cultured adult rat ventricular myocytes [J].Forensic Sci Int,2000,113(1-3):239-243.
[41] Maeno Y, Iwasa M, Inoue H,et al. Methamphetamine induces an increase incell size and reorganization of myofibrils in cultured adult rat cardiomyocytes[J]. Int J Legal Med,2000,113(4):201-207.
[42] Cerretani D, Riezzo I, Fiaschi AI,et al. Cardiac oxidative stress determinationand myocardial morphology after a single ecstasy (MDMA) administration ina rat model [J]. Int J Legal Med,2008,122(6):461-469.
[43] Shenouda SK, Lord KC, McIlwain E,et al. Ecstasy produces left ventriculardysfunction and oxidative stress in rats [J]. Cardiovasc Res,2008,79(4):662-670.
[44] Dumont GJ, Verkes RJ. A review of acute effects of3,4-methylenedioxymethamphetamine in healthy volunteers [J]. JPsychopharmacol,2006,20(2):176-187.
[45] Outslay MG. Understanding ecstasy [J]. JAAPA,2006,19(7):42-47.
[46] Lester SJ, Baggott M, Welm S,et al. Cardiovascular effects of3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlledtrial [J]. Ann Intern Med,2000,133(12):969-973.
[47] de la Torre R, Farre M, Roset PN,et al. Pharmacology of MDMA in humans[J]. Ann N Y Acad Sci,2000,914(225-237.
[48]冯雪芳,吕剑杰,张铁营,et al.苯丙胺类兴奋剂急性中毒65例临床分析[J].实用医学杂志,2010,26(18):2.
[49]邱泽武,孙成文,蓝红,et al.苯丙胺类兴奋剂急性中毒12例临床分析[J].中华内科杂志,2002,41(11):2.
[50] Olgar S, Dindar A, Ertugrul T,et al. Electrocardiographic andechocardiographic findings in street children known to be substance abusers[J]. Cardiol Young,2008,18(1):58-61.
[51] Beardslee MA, Lerner DL, Tadros PN,et al. Dephosphorylation andintracellular redistribution of ventricular connexin43during electricaluncoupling induced by ischemia [J]. Circ Res,2000,87(8):656-662.
[52] Joyner RW. Effects of the discrete pattern of electrical coupling onpropagation through an electrical syncytium [J]. Circ Res,1982,50(2):192-200.
[53] Spach MS, Heidlage JF. The stochastic nature of cardiac propagation at amicroscopic level. Electrical description of myocardial architecture and itsapplication to conduction [J]. Circ Res,1995,76(3):366-380.
[54] Neri M, Bello S, Bonsignore A,et al. Myocardial expression of TNF-alpha,IL-1beta, IL-6, IL-8, IL-10and MCP-1after a single MDMA doseadministered in a rat model [J]. Curr Pharm Biotechnol,2010,11(5):413-420.
[55] Fernandez-Cobo M, Gingalewski C, Drujan D,et al. Downregulation ofconnexin43gene expression in rat heart during inflammation. The role oftumour necrosis factor [J]. Cytokine,1999,11(3):216-224.
[56]赵苳,曹家琪,刘志民,et al. MDMA研究进展[J].中国药物依赖性杂志,2001,10(3):1.
[1] Bolton JL, Trush MA, Penning TM,et al. Role of quinones in toxicology [J].Chem Res Toxicol,2000,13(3):135-160.
[2] Carvalho M, Remiao F, Milhazes N,et al. Metabolism is required for theexpression of ecstasy-induced cardiotoxicity in vitro [J]. Chem Res Toxicol,2004,17(5):623-632.
[3] Carvalho M, Hawksworth G, Milhazes N,et al. Role of metabolites in MDMA(ecstasy)-induced nephrotoxicity: an in vitro study using rat and human renalproximal tubular cells [J]. Arch Toxicol,2002,76(10):581-588.
[4] Shenouda SK, Varner KJ, Carvalho F,et al. Metabolites of MDMA induceoxidative stress and contractile dysfunction in adult rat left ventricularmyocytes [J]. Cardiovasc Toxicol,2009,9(1):30-38.
[5] Carvalho M, Remiao F, Milhazes N,et al. The toxicity ofN-methyl-alpha-methyldopamine to freshly isolated rat hepatocytes isprevented by ascorbic acid and N-acetylcysteine [J]. Toxicology,2004,200(2-3):193-203.
[6] Yamashita N, Nishida M, Hoshida S,et al. Induction of manganese superoxidedismutase in rat cardiac myocytes increases tolerance to hypoxia24hoursafter preconditioning [J]. J Clin Invest,1994,94(6):2193-2199.
[7] Estevez MD, Wolf A, Schramm U. Effect of PSC833, verapamil andamiodarone on adriamycin toxicity in cultured rat cardiomyocytes [J]. ToxicolIn Vitro,2000,14(1):17-23.
[8] Nishio M, Ruch SW, Kelly JE,et al. Ouabain increases sarcoplasmic reticulumcalcium release in cardiac myocytes [J]. J Pharmacol Exp Ther,2004,308(3):1181-1190.
[9] Kimes BW, Brandt BL. Properties of a clonal muscle cell line from rat heart[J]. Exp Cell Res,1976,98(2):367-381.
[10] Hescheler J, Meyer R, Plant S,et al. Morphological, biochemical, andelectrophysiological characterization of a clonal cell (H9c2) line from rat heart[J]. Circ Res,1991,69(6):1476-1486.
[11] Sipido KR, Marban E. L-type calcium channels, potassium channels, andnovel nonspecific cation channels in a clonal muscle cell line derived fromembryonic rat ventricle [J]. Circ Res,1991,69(6):1487-1499.
[12] Zimmermann WH, Schneiderbanger K, Schubert P,et al. Tissue engineering ofa differentiated cardiac muscle construct [J]. Circ Res,2002,90(2):223-230.
[13] Blondel B, Roijen I, Cheneval JP. Heart cells in culture: a simple method forincreasing the proportion of myoblasts [J]. Experientia,1971,27(3):356-358.
[14] Brooks G, Poolman RA, McGill CJ,et al. Expression and activities of cyclinsand cyclin-dependent kinases in developing rat ventricular myocytes [J]. J MolCell Cardiol,1997,29(8):2261-2271.
[15] Simpson P, Savion S. Differentiation of rat myocytes in single cell cultureswith and without proliferating nonmyocardial cells. Cross-striations,ultrastructure, and chronotropic response to isoproterenol [J]. Circ Res,1982,50(1):101-116.
[16] de la Torre R, Farre M, Roset PN,et al. Human pharmacology of MDMA:pharmacokinetics, metabolism, and disposition [J]. Ther Drug Monit,2004,26(2):137-144.
[17] Verheyden SL, Henry JA, Curran HV. Acute, sub-acute and long-termsubjective consequences of 'ecstasy'(MDMA) consumption in430regularusers [J]. Hum Psychopharmacol,2003,18(7):507-517.
[18] Elliott SP. MDMA and MDA concentrations in antemortem and postmortemspecimens in fatalities following hospital admission [J]. J Anal Toxicol,2005,29(5):296-300.
[19] Zhang B, Green JV, Murthy SK,et al. Label-free enrichment of functionalcardiomyocytes using microfluidic deterministic lateral flow displacement [J].PLoS One,2012,7(5): e37619.
[20] Yuan Ye K, Sullivan KE, Black LD. Encapsulation of cardiomyocytes in afibrin hydrogel for cardiac tissue engineering [J]. J Vis Exp,2011,55).
[21] Jang J, Ku SY, Kim JE,et al. Notch inhibition promotes human embryonicstem cell-derived cardiac mesoderm differentiation [J]. Stem Cells,2008,26(11):2782-2790.
[22] LaFramboise WA, Scalise D, Stoodley P,et al. Cardiac fibroblasts influencecardiomyocyte phenotype in vitro [J]. Am J Physiol Cell Physiol,2007,292(5):C1799-1808.
[23] Entcheva E, Bien H, Yin L,et al. Functional cardiac cell constructs oncellulose-based scaffolding [J]. Biomaterials,2004,25(26):5753-5762.
[24] Chen HH, Mullett SJ, Stewart AF. Vgl-4, a novel member of the vestigial-likefamily of transcription cofactors, regulates alpha1-adrenergic activation ofgene expression in cardiac myocytes [J]. J Biol Chem,2004,279(29):30800-30806.
[25] Tamamori-Adachi M, Hayashida K, Nobori K,et al. Down-regulation ofp27Kip1promotes cell proliferation of rat neonatal cardiomyocytes inducedby nuclear expression of cyclin D1and CDK4. Evidence for impairedSkp2-dependent degradation of p27in terminal differentiation [J]. J BiolChem,2004,279(48):50429-50436.
[26] Tamamori-Adachi M, Ito H, Sumrejkanchanakij P,et al. Critical role of cyclinD1nuclear import in cardiomyocyte proliferation [J]. Circ Res,2003,92(1):e12-19.
[27] Arutunyan A, Webster DR, Swift LM,et al. Localized injury in cardiomyocytenetwork: a new experimental model of ischemia-reperfusion arrhythmias [J].Am J Physiol Heart Circ Physiol,2001,280(4): H1905-1915.
[28] Bueno OF, De Windt LJ, Tymitz KM,et al. The MEK1-ERK1/2signalingpathway promotes compensated cardiac hypertrophy in transgenic mice [J].EMBO J,2000,19(23):6341-6350.
[29] Nemec J, Wickman K, Clapham DE. Gbetagamma binding increases the opentime of IKACh: kinetic evidence for multiple Gbetagamma binding sites [J].Biophys J,1999,76(1Pt1):246-252.
[30] Adderley SR, Fitzgerald DJ. Oxidative damage of cardiomyocytes is limitedby extracellular regulated kinases1/2-mediated induction of cyclooxygenase-2[J]. J Biol Chem,1999,274(8):5038-5046.
[31] Reinecke H, Zhang M, Bartosek T,et al. Survival, integration, anddifferentiation of cardiomyocyte grafts: a study in normal and injured rathearts [J]. Circulation,1999,100(2):193-202.
[32] VanWinkle WB, Snuggs MB, Buja LM. Cardiogel: a biosynthetic extracellularmatrix for cardiomyocyte culture [J]. In Vitro Cell Dev Biol Anim,1996,32(8):478-485.
[33] Li RK, Mickle DA, Weisel RD,et al. In vivo survival and function oftransplanted rat cardiomyocytes [J]. Circ Res,1996,78(2):283-288.
[34] Marino TA, Walter RA, Cobb E,et al. Effects of norepinephrine on neonatalrat cardiocyte growth and differentiation [J]. In Vitro Cell Dev Biol,1990,26(3Pt1):229-236.
[35] Toraason M, Luken ME, Breitenstein M,et al. Comparative toxicity ofallylamine and acrolein in cultured myocytes and fibroblasts from neonatal ratheart [J]. Toxicology,1989,56(1):107-117.
[36] Grynberg A, Degois M, Guenot L,et al. Primary rat cardiac cell culture: diet ofthe mother rats as a determinant parameter of cardiomyoblast production fromneonates [J]. Biol Cell,1986,57(1):89-91.
[37] Jongsma HJ, Wilders R. Gap junctions in cardiovascular disease [J]. Circ Res,2000,86(12):1193-1197.
[38] Fontes MS, van Veen TA, de Bakker JM,et al. Functional consequences ofabnormal Cx43expression in the heart [J]. Biochim Biophys Acta,2012,1818(8):2020-2029.
[39] Kumar NM, Gilula NB. The gap junction communication channel [J]. Cell,1996,84(3):381-388.
[40] Saez JC, Berthoud VM, Branes MC,et al. Plasma membrane channels formedby connexins: their regulation and functions [J]. Physiol Rev,2003,83(4):1359-1400.
[41] Sohl G, Willecke K. Gap junctions and the connexin protein family [J].Cardiovasc Res,2004,62(2):228-232.
[42] Zeevi-Levin N, Barac YD, Reisner Y,et al. Gap junctional remodeling byhypoxia in cultured neonatal rat ventricular myocytes [J]. Cardiovasc Res,2005,66(1):64-73.
[43] Gourdie RG, Green CR, Severs NJ,et al. Immunolabelling patterns of gapjunction connexins in the developing and mature rat heart [J]. Anat Embryol(Berl),1992,185(4):363-378.
[44] Kwak BR, van Kempen MJ, Theveniau-Ruissy M,et al. Connexin expressionin cultured neonatal rat myocytes reflects the pattern of the intact ventricle [J].Cardiovasc Res,1999,44(2):370-380.
[45] Thiriet N, Ladenheim B, McCoy MT,et al. Analysis of ecstasy(MDMA)-induced transcriptional responses in the rat cortex [J]. FASEB J,2002,16(14):1887-1894.
[46] Tiangco DA, Lattanzio FA, Jr., Osgood CJ,et al.3,4-Methylenedioxymethamphetamine activates nuclear factor-kappaB,increases intracellular calcium, and modulates gene transcription in rat heartcells [J]. Cardiovasc Toxicol,2005,5(3):301-310.
[47] Alonso F, Krattinger N, Mazzolai L,et al. An angiotensin II-andNF-B-dependent mechanism increases connexin43in murine arteriestargeted by renin-dependent hypertension [J]. Cardiovascular Research,2010,87(1):166-176.
[48] Tornatore L, Thotakura AK, Bennett J,et al. The nuclear factor kappa Bsignaling pathway: integrating metabolism with inflammation [J]. Trends CellBiol,2012,22(11):557-566.
[49] Fernandez-Cobo M, Gingalewski C, Drujan D,et al. Downregulation ofconnexin43gene expression in rat heart during inflammation. The role oftumour necrosis factor [J]. Cytokine,1999,11(3):216-224.
[50] Gumbiner BM. Regulation of cadherin-mediated adhesion in morphogenesis[J]. Nat Rev Mol Cell Biol,2005,6(8):622-634.
[51] Angst BD, Khan LU, Severs NJ,et al. Dissociated spatial patterning of gapjunctions and cell adhesion junctions during postnatal differentiation ofventricular myocardium [J]. Circ Res,1997,80(1):88-94.
[52] Hertig CM, Butz S, Koch S,et al. N-cadherin in adult rat cardiomyocytes inculture. II. Spatio-temporal appearance of proteins involved in cell-cell contactand communication. Formation of two distinct N-cadherin/catenin complexes[J]. J Cell Sci,1996,109(Pt1)(11-20.
[53] Shaw RM, Fay AJ, Puthenveedu MA,et al. Microtubule plus-end-trackingproteins target gap junctions directly from the cell interior to adherensjunctions [J]. Cell,2007,128(3):547-560.
[54] Wei CJ, Francis R, Xu X,et al. Connexin43associated with anN-cadherin-containing multiprotein complex is required for gap junctionformation in NIH3T3cells [J]. J Biol Chem,2005,280(20):19925-19936.
[55] Li J, Patel VV, Kostetskii I,et al. Cardiac-specific loss of N-cadherin leads toalteration in connexins with conduction slowing and arrhythmogenesis [J].Circ Res,2005,97(5):474-481.
[56] Solan JL, Lampe PD. Connexin43phosphorylation: structural changes andbiological effects [J]. Biochem J,2009,419(2):261-272.
[57] Lampe PD, Lau AF. The effects of connexin phosphorylation on gapjunctional communication [J]. Int J Biochem Cell Biol,2004,36(7):1171-1186.
[58] Laird DW, Puranam KL, Revel JP. Turnover and phosphorylation dynamics ofconnexin43gap junction protein in cultured cardiac myocytes [J]. Biochem J,1991,273(Pt1)(67-72.
[59] Beardslee MA, Laing JG, Beyer EC,et al. Rapid turnover of connexin43in theadult rat heart [J]. Circ Res,1998,83(6):629-635.
[60] VanSlyke JK, Deschenes SM, Musil LS. Intracellular transport, assembly, anddegradation of wild-type and disease-linked mutant gap junction proteins [J].Mol Biol Cell,2000,11(6):1933-1946.
[61] Harris AL. Emerging issues of connexin channels: biophysics fills the gap [J].Q Rev Biophys,2001,34(3):325-472.
[1] Urschel S, Hoher T, Schubert T,et al. Protein kinase A-mediatedphosphorylation of connexin36in mouse retina results in decreased gapjunctional communication between AII amacrine cells [J]. J Biol Chem,2006,281(44):33163-33171.
[2] Lampe PD, Lau AF. Regulation of gap junctions by phosphorylation ofconnexins [J]. Arch Biochem Biophys,2000,384(2):205-215.
[3] Warn-Cramer BJ, Kurata WE, Lau AF. Biochemical analysis of connexinphosphorylation [J]. Methods Mol Biol,2001,154(431-446.
[4] Lampe PD, Lau AF. The effects of connexin phosphorylation on gapjunctional communication [J]. Int J Biochem Cell Biol,2004,36(7):1171-1186.
[5] Yogo K, Ogawa T, Akiyama M,et al. PKA implicated in the phosphorylationof Cx43induced by stimulation with FSH in rat granulosa cells [J]. J ReprodDev,2006,52(3):321-328.
[6] Berthoud VM, Ledbetter ML, Hertzberg EL,et al. Connexin43in MDCK cells:regulation by a tumor-promoting phorbol ester and Ca2+[J]. Eur J Cell Biol,1992,57(1):40-50.
[7] Reynhout JK, Lampe PD, Johnson RG. An activator of protein kinase Cinhibits gap junction communication between cultured bovine lens cells [J].Exp Cell Res,1992,198(2):337-342.
[8] Kanemitsu MY, Jiang W, Eckhart W. Cdc2-mediated phosphorylation of thegap junction protein, connexin43, during mitosis [J]. Cell Growth Differ,1998,9(1):13-21.
[9] Lampe PD, Kurata WE, Warn-Cramer BJ,et al. Formation of a distinctconnexin43phosphoisoform in mitotic cells is dependent upon p34cdc2kinase[J]. J Cell Sci,1998,111(Pt6)(833-841.
[10] Cooper CD, Lampe PD. Casein kinase1regulates connexin-43gap junctionassembly [J]. J Biol Chem,2002,277(47):44962-44968.
[11] Warn-Cramer BJ, Cottrell GT, Burt JM,et al. Regulation of connexin-43gapjunctional intercellular communication by mitogen-activated protein kinase [J].J Biol Chem,1998,273(15):9188-9196.
[12] Cameron SJ, Malik S, Akaike M,et al. Regulation of epidermal growthfactor-induced connexin43gap junction communication by bigmitogen-activated protein kinase1/ERK5but not ERK1/2kinase activation [J].J Biol Chem,2003,278(20):18682-18688.
[13] Loo LW, Berestecky JM, Kanemitsu MY,et al. pp60src-mediatedphosphorylation of connexin43, a gap junction protein [J]. J Biol Chem,1995,270(21):12751-12761.
[14] Swenson KI, Piwnica-Worms H, McNamee H,et al. Tyrosine phosphorylationof the gap junction protein connexin43is required for the pp60v-src-inducedinhibition of communication [J]. Cell Regul,1990,1(13):989-1002.
[15] Ek-Vitorin JF, King TJ, Heyman NS,et al. Selectivity of connexin43channelsis regulated through protein kinase C-dependent phosphorylation [J]. Circ Res,2006,98(12):1498-1505.
[16] Zhang SW, Liu Y, Huang GZ,et al. Aconitine alters connexin43phosphorylation status and [Ca2+] oscillation patterns in cultured ventricularmyocytes of neonatal rats [J]. Toxicol In Vitro,2007,21(8):1476-1485.
[17] Hund TJ, Lerner DL, Yamada KA,et al. Protein kinase Cepsilon mediatessalutary effects on electrical coupling induced by ischemic preconditioning [J].Heart Rhythm,2007,4(9):1183-1193.
[18] Guggilam A, Hutchinson KR, West TA,et al. In vivo and in vitro cardiacresponses to beta-adrenergic stimulation in volume-overload heart failure [J]. JMol Cell Cardiol,2013,57(47-58.
[19] O'Quinn MP, Palatinus JA, Harris BS,et al. A peptide mimetic of theconnexin43carboxyl terminus reduces gap junction remodeling and inducedarrhythmia following ventricular injury [J]. Circ Res,2011,108(6):704-715.
[20] Saez JC, Nairn AC, Czernik AJ,et al. Phosphorylation of connexin43and theregulation of neonatal rat cardiac myocyte gap junctions [J]. J Mol CellCardiol,1997,29(8):2131-2145.
[21] Brissette JL, Kumar NM, Gilula NB,et al. The tumor promoter12-O-tetradecanoylphorbol-13-acetate and the ras oncogene modulateexpression and phosphorylation of gap junction proteins [J]. Mol Cell Biol,1991,11(10):5364-5371.
[22] Lampe PD. Analyzing phorbol ester effects on gap junctional communication:a dramatic inhibition of assembly [J]. J Cell Biol,1994,127(6Pt2):1895-1905.
[23] Kwak BR, van Veen TA, Analbers LJ,et al. TPA increases conductance butdecreases permeability in neonatal rat cardiomyocyte gap junction channels [J].Exp Cell Res,1995,220(2):456-463.
[24] Mellor H, Parker PJ. The extended protein kinase C superfamily [J]. BiochemJ,1998,332(Pt2)(281-292.
[25] Nishizuka Y. Protein kinase C and lipid signaling for sustained cellularresponses [J]. FASEB J,1995,9(7):484-496.
[26] Liang JY, Wang SM, Chung TH,et al. Effects of18-glycyrrhetinic acid onserine368phosphorylation of connexin43in rat neonatal cardiomyocytes [J].Cell Biol Int,2008,32(11):1371-1379.
[27] Palatinus JA, Rhett JM, Gourdie RG. Enhanced PKCepsilon mediatedphosphorylation of connexin43at serine368by a carboxyl-terminal mimeticpeptide is dependent on injury [J]. Channels (Austin),2011,5(3):236-240.
[28] Harberd N, Artavanis-Tsakonas S, Berridge MJ,et al. Cell communication. In:Alberts B, Johnson A, Lewis J, et al.(eds). Molecular Biology of the Cell NewYork Garland Science,2002:831-906.
[29] Dempsey EC, Newton AC, Mochly-Rosen D,et al. Protein kinase C isozymesand the regulation of diverse cell responses [J]. Am J Physiol Lung Cell MolPhysiol,2000,279(3): L429-438.
[30] Melloni E, Pontremoli S, Michetti M,et al. Binding of protein kinase C toneutrophil membranes in the presence of Ca2+and its activation by aCa2+-requiring proteinase [J]. Proc Natl Acad Sci U S A,1985,82(19):6435-6439.
[31] Garcia-Rates S, Camarasa J, Sanchez-Garcia AI,et al. The effects of3,4-methylenedioxymethamphetamine (MDMA) on nicotinic receptors:intracellular calcium increase, calpain/caspase3activation, and functionalupregulation [J]. Toxicol Appl Pharmacol,2010,244(3):344-353.
[32] Beitia G, Cobreros A, Sainz L,et al.3,4-Methylenedioxymethamphetamine(ecstasy)-induced hepatotoxicity: effect on cytosolic calcium signals inisolated hepatocytes [J]. Liver,1999,19(3):234-241.
[33] Azmitia EC, Murphy RB, Whitaker-Azmitia PM. MDMA (ecstasy) effects oncultured serotonergic neurons: evidence for Ca2(+)-dependent toxicity linkedto release [J]. Brain Res,1990,510(1):97-103.
[34] Shenouda SK, Varner KJ, Carvalho F,et al. Metabolites of MDMA induceoxidative stress and contractile dysfunction in adult rat left ventricularmyocytes [J]. Cardiovasc Toxicol,2009,9(1):30-38.
[35] Tiangco DA, Lattanzio FA, Jr., Osgood CJ,et al.3,4-Methylenedioxymethamphetamine activates nuclear factor-kappaB,increases intracellular calcium, and modulates gene transcription in rat heartcells [J]. Cardiovasc Toxicol,2005,5(3):301-310.
[36] Cerretani D, Riezzo I, Fiaschi AI,et al. Cardiac oxidative stress determinationand myocardial morphology after a single ecstasy (MDMA) administration ina rat model [J]. Int J Legal Med,2008,122(6):461-469.
[37] Li C, Meng Q, Yu X,et al. Regulatory effect of connexin43on basal Ca2+signaling in rat ventricular myocytes [J]. PLoS One,2012,7(4): e36165.
[1]孙毅,徐本树,王志强,et al.250例苯丙胺类摇头丸（MDMA）滥用人群分析[J].中国药物滥用防治杂志,2004,10(5):3.
[2]郑少攀,卢延旭.苯丙胺类兴奋剂的法医毒理学研究进展[J].中国法医学杂志,2004,19(1):2.
[3] Green AR, Cross AJ, Goodwin GM. Review of the pharmacology and clinicalpharmacology of3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy")[J]. Psychopharmacology (Berl),1995,119(3):247-260.
[4] Kalant H. The pharmacology and toxicology of "ecstasy"(MDMA) andrelated drugs [J]. CMAJ,2001,165(7):917-928.
[5] Lester SJ, Baggott M, Welm S,et al. Cardiovascular effects of3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlledtrial [J]. Ann Intern Med,2000,133(12):969-973.
[6] Badon LA, Hicks A, Lord K,et al. Changes in cardiovascular responsivenessand cardiotoxicity elicited during binge administration of Ecstasy [J]. JPharmacol Exp Ther,2002,302(3):898-907.
[7] Hysek CM, Brugger R, Simmler LD,et al. Effects of the alpha(2)-adrenergicagonist clonidine on the pharmacodynamics and pharmacokinetics of3,4-methylenedioxymethamphetamine in healthy volunteers [J]. J PharmacolExp Ther,2012,340(2):286-294.
[8] Fitzgerald JL, Reid JJ. Sympathomimetic actions ofmethylenedioxymethamphetamine in rat and rabbit isolated cardiovasculartissues [J]. J Pharm Pharmacol,1994,46(10):826-832.
[9] Olgar S, Dindar A, Ertugrul T,et al. Electrocardiographic andechocardiographic findings in street children known to be substance abusers[J]. Cardiol Young,2008,18(1):58-61.
[10] Yeo KK, Wijetunga M, Ito H,et al. The association of methamphetamine useand cardiomyopathy in young patients [J]. Am J Med,2007,120(2):165-171.
[11] Mizia-Stec K, Gasior Z, Wojnicz R,et al. Severe dilated cardiomyopathy as aconsequence of Ecstasy intake [J]. Cardiovasc Pathol,2008,17(4):250-253.
[12] Dowling GP, McDonough ET,3rd, Bost RO.'Eve' and 'Ecstasy'. A report offive deaths associated with the use of MDEA and MDMA [J]. JAMA,1987,257(12):1615-1617.
[13] Gesi M, Lenzi P, Soldani P,et al. Morphological effects in the mousemyocardium after methylenedioxymethamphetamine administration combinedwith loud noise exposure [J]. Anat Rec,2002,267(1):37-46.
[14] Virmani R, Robinowitz M, Smialek JE,et al. Cardiovascular effects of cocaine:an autopsy study of40patients [J]. Am Heart J,1988,115(5):1068-1076.
[15] Gesi M, Soldani P, Lenzi P,et al. Ecstasy during loud noise exposure inducesdramatic ultrastructural changes in the heart [J]. Pharmacol Toxicol,2002,91(1):29-33.
[16] Madhok A, Boxer R, Chowdhury D. Atrial fibrillation in an adolescent--theagony of ecstasy [J]. Pediatr Emerg Care,2003,19(5):348-349.
[17] Diffley M, Armenian P, Gerona R,et al. Catecholaminergic polymorphicventricular tachycardia found in an adolescent after amethylenedioxymethamphetamine and marijuana-induced cardiac arrest [J].Crit Care Med,2012,40(7):2223-2226.
[18] Patel MM, Belson MG, Wright D,et al. Methylenedioxymethamphetamine(ecstasy)-related myocardial hypertrophy: an autopsy study [J]. Resuscitation,2005,66(2):197-202.
[19] Karch SB, Green GS, Young S. Myocardial hypertrophy and coronary arterydisease in male cocaine users [J]. J Forensic Sci,1995,40(4):591-595.
[20] Henning RJ, Silva J, Reddy V,et al. Cocaine increases beta-myosinheavy-chain protein expression in cardiac myocytes [J]. J CardiovascPharmacol Ther,2000,5(4):313-322.
[21] Karch SB, Stephens BG, Ho CH. Methamphetamine-related deaths in SanFrancisco: demographic, pathologic, and toxicologic profiles [J]. J ForensicSci,1999,44(2):359-368.
[22] Kaye S, Darke S, Duflou J. Methylenedioxymethamphetamine(MDMA)-related fatalities in Australia: demographics, circumstances,toxicology and major organ pathology [J]. Drug Alcohol Depend,2009,104(3):254-261.
[23] Wijetunga M, Seto T, Lindsay J,et al. Crystal methamphetamine-associatedcardiomyopathy: tip of the iceberg?[J]. J Toxicol Clin Toxicol,2003,41(7):981-986.
[24] Milroy CM, Clark JC, Forrest AR. Pathology of deaths associated with"ecstasy" and "eve" misuse [J]. J Clin Pathol,1996,49(2):149-153.
[25] He SY, Matoba R, Fujitani N,et al. Cardiac muscle lesions associated withchronic administration of methamphetamine in rats [J]. Am J Forensic MedPathol,1996,17(2):155-162.
[26] Maeno Y, Iwasa M, Inoue H,et al. Direct effects of methamphetamine onhypertrophy and microtubules in cultured adult rat ventricular myocytes [J].Forensic Sci Int,2000,113(1-3):239-243.
[27] Cerretani D, Riezzo I, Fiaschi AI,et al. Cardiac oxidative stress determinationand myocardial morphology after a single ecstasy (MDMA) administration ina rat model [J]. Int J Legal Med,2008,122(6):461-469.
[28] Fineschi V, Centini F, Mazzeo E,et al. Adam (MDMA) and Eve (MDEA)misuse: an immunohistochemical study on three fatal cases [J]. Forensic SciInt,1999,104(1):65-74.
[29] Maeno Y, Iwasa M, Inoue H,et al. Methamphetamine induces an increase incell size and reorganization of myofibrils in cultured adult rat cardiomyocytes[J]. Int J Legal Med,2000,113(4):201-207.
[30] Carvalho M, Remiao F, Milhazes N,et al. Metabolism is required for theexpression of ecstasy-induced cardiotoxicity in vitro [J]. Chem Res Toxicol,2004,17(5):623-632.
[31] Bexis S, Docherty JR. Effects of MDMA, MDA and MDEA on blood pressure,heart rate, locomotor activity and body temperature in the rat involvealpha-adrenoceptors [J]. Br J Pharmacol,2006,147(8):926-934.
[32] Hysek CM, Simmler LD, Ineichen M,et al. The norepinephrine transporterinhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans[J]. Clin Pharmacol Ther,2011,90(2):246-255.
[33] Mas M, Farre M, de la Torre R,et al. Cardiovascular and neuroendocrineeffects and pharmacokinetics of3,4-methylenedioxymethamphetamine inhumans [J]. J Pharmacol Exp Ther,1999,290(1):136-145.
[34] Turillazzi E, Riezzo I, Neri M,et al. MDMA toxicity and pathologicalconsequences: a review about experimental data and autopsy findings [J]. CurrPharm Biotechnol,2010,11(5):500-509.
[35] Rona G. Catecholamine cardiotoxicity [J]. J Mol Cell Cardiol,1985,17(4):291-306.
[36] Wheatley AM, Thandroyen FT, Opie LH. Catecholamine-induced myocardialcell damage: catecholamines or adrenochrome [J]. J Mol Cell Cardiol,1985,17(4):349-359.
[37] O'Cain PA, Hletko SB, Ogden BA,et al. Cardiovascular and sympatheticresponses and reflex changes elicited by MDMA [J]. Physiol Behav,2000,70(1-2):141-148.
[38] Shenouda SK, Lord KC, McIlwain E,et al. Ecstasy produces left ventriculardysfunction and oxidative stress in rats [J]. Cardiovasc Res,2008,79(4):662-670.
[39] Tiangco DA, Lattanzio FA, Jr., Osgood CJ,et al.3,4-Methylenedioxymethamphetamine activates nuclear factor-kappaB,increases intracellular calcium, and modulates gene transcription in rat heartcells [J]. Cardiovasc Toxicol,2005,5(3):301-310.
[40] Cleary L, Docherty JR. Actions of amphetamine derivatives and cathinone atthe noradrenaline transporter [J]. Eur J Pharmacol,2003,476(1-2):31-34.
[41] Schifano F, Oyefeso A, Webb L,et al. Review of deaths related to takingecstasy, England and Wales,1997-2000[J]. BMJ,2003,326(7380):80-81.
[42] McDaid J, Docherty JR. Vascular actions of MDMA involve alpha1andalpha2-adrenoceptors in the anaesthetized rat [J]. Br J Pharmacol,2001,133(3):429-437.
[43] Carvalho M, Remiao F, Milhazes N,et al. The toxicity ofN-methyl-alpha-methyldopamine to freshly isolated rat hepatocytes isprevented by ascorbic acid and N-acetylcysteine [J]. Toxicology,2004,200(2-3):193-203.
[44] Shenouda SK, Varner KJ, Carvalho F,et al. Metabolites of MDMA induceoxidative stress and contractile dysfunction in adult rat left ventricularmyocytes [J]. Cardiovasc Toxicol,2009,9(1):30-38.
[45] Neri M, Bello S, Bonsignore A,et al. Myocardial expression of TNF-alpha,IL-1beta, IL-6, IL-8, IL-10and MCP-1after a single MDMA doseadministered in a rat model [J]. Curr Pharm Biotechnol,2010,11(5):413-420.
[46] Eddahibi S, Raffestin B, Hamon M,et al. Is the serotonin transporter involvedin the pathogenesis of pulmonary hypertension?[J]. J Lab Clin Med,2002,139(4):194-201.
[47] Droogmans S, Cosyns B, D'Haenen H,et al. Possible association between3,4-methylenedioxymethamphetamine abuse and valvular heart disease [J].Am J Cardiol,2007,100(9):1442-1445.
[48] Sano R, Hasuike T, Nakano M,et al. A fatal case of myocardial damage due tomisuse of the "designer drug" MDMA [J]. Leg Med (Tokyo),2009,11(6):294-297.
[2] Crespi D, Mennini T, Gobbi M. Carrier-dependent and Ca(2+)-dependent5-HT and dopamine release induced by (+)-amphetamine,3,4-methylendioxymethamphetamine, p-chloroamphetamine and(+)-fenfluramine [J]. Br J Pharmacol,1997,121(8):1735-1743.
[3] Vollenweider FX, Gamma A, Liechti M,et al. Psychological andcardiovascular effects and short-term sequelae of MDMA ("ecstasy") inMDMA-naive healthy volunteers [J]. Neuropsychopharmacology,1998,19(4):241-251.
[4] Cohen RS, Cocores J. Neuropsychiatric manifestations following the use of3,4-methylenedioxymethamphetamine (MDMA:"Ecstasy")[J]. ProgNeuropsychopharmacol Biol Psychiatry,1997,21(4):727-734.
[5] Kolbrich EA, Goodwin RS, Gorelick DA,et al. Physiological and subjectiveresponses to controlled oral3,4-methylenedioxymethamphetamineadministration [J]. J Clin Psychopharmacol,2008,28(4):432-440.
[6]孙毅,徐本树,王志强,et al.250例苯丙胺类摇头丸（MDMA）滥用人群分析[J].中国药物滥用防治杂志,2004,10(5):3.
[7] Crean RD, Davis SA, Von Huben SN,et al. Effects of(+/-)3,4-methylenedioxymethamphetamine,(+/-)3,4-methylenedioxyamphetamine and methamphetamine on temperatureand activity in rhesus macaques [J]. Neuroscience,2006,142(2):515-525.
[8] Hall AP, Henry JA. Acute toxic effects of 'Ecstasy'(MDMA) and relatedcompounds: overview of pathophysiology and clinical management [J]. Br JAnaesth,2006,96(6):678-685.
[9] Sprague JE, Preston AS, Leifheit M,et al. Hippocampal serotonergic damageinduced by MDMA (ecstasy): effects on spatial learning [J]. Physiol Behav,2003,79(2):281-287.
[10] Badon LA, Hicks A, Lord K,et al. Changes in cardiovascular responsivenessand cardiotoxicity elicited during binge administration of Ecstasy [J]. JPharmacol Exp Ther,2002,302(3):898-907.
[11] Gesi M, Lenzi P, Soldani P,et al. Morphological effects in the mousemyocardium after methylenedioxymethamphetamine administration combinedwith loud noise exposure [J]. Anat Rec,2002,267(1):37-46.
[12] Gesi M, Soldani P, Lenzi P,et al. Ecstasy during loud noise exposure inducesdramatic ultrastructural changes in the heart [J]. Pharmacol Toxicol,2002,91(1):29-33.
[13] Kaye S, Darke S, Duflou J. Methylenedioxymethamphetamine(MDMA)-related fatalities in Australia: demographics, circumstances,toxicology and major organ pathology [J]. Drug Alcohol Depend,2009,104(3):254-261.
[14] Yeo KK, Wijetunga M, Ito H,et al. The association of methamphetamine useand cardiomyopathy in young patients [J]. Am J Med,2007,120(2):165-171.
[15] Mas M, Farre M, de la Torre R,et al. Cardiovascular and neuroendocrineeffects and pharmacokinetics of3,4-methylenedioxymethamphetamine inhumans [J]. J Pharmacol Exp Ther,1999,290(1):136-145.
[16] Madhok A, Boxer R, Chowdhury D. Atrial fibrillation in an adolescent--theagony of ecstasy [J]. Pediatr Emerg Care,2003,19(5):348-349.
[17] Diffley M, Armenian P, Gerona R,et al. Catecholaminergic polymorphicventricular tachycardia found in an adolescent after amethylenedioxymethamphetamine and marijuana-induced cardiac arrest [J].Crit Care Med,2012,40(7):2223-2226.
[18] O'Cain PA, Hletko SB, Ogden BA,et al. Cardiovascular and sympatheticresponses and reflex changes elicited by MDMA [J]. Physiol Behav,2000,70(1-2):141-148.
[19] Bolton JL, Trush MA, Penning TM,et al. Role of quinones in toxicology [J].Chem Res Toxicol,2000,13(3):135-160.
[20] Carvalho M, Remiao F, Milhazes N,et al. Metabolism is required for theexpression of ecstasy-induced cardiotoxicity in vitro [J]. Chem Res Toxicol,2004,17(5):623-632.
[21] Carvalho M, Hawksworth G, Milhazes N,et al. Role of metabolites in MDMA(ecstasy)-induced nephrotoxicity: an in vitro study using rat and human renalproximal tubular cells [J]. Arch Toxicol,2002,76(10):581-588.
[22] Saez JC, Berthoud VM, Branes MC,et al. Plasma membrane channels formedby connexins: their regulation and functions [J]. Physiol Rev,2003,83(4):1359-1400.
[23] Elfgang C, Eckert R, Lichtenberg-Frate H,et al. Specific permeability andselective formation of gap junction channels in connexin-transfected HeLacells [J]. J Cell Biol,1995,129(3):805-817.
[24] Wilkins AS. Gap junction-mediated intercellular signalling in health anddisease [J]. Bioessays,1998,20(8):686-688.
[25] Dhein S. Gap junction channels in the cardiovascular system: pharmacologicaland physiological modulation [J]. Trends Pharmacol Sci,1998,19(6):229-241.
[26] Urschel S, Hoher T, Schubert T,et al. Protein kinase A-mediatedphosphorylation of connexin36in mouse retina results in decreased gapjunctional communication between AII amacrine cells [J]. J Biol Chem,2006,281(44):33163-33171.
[27] Tribulova N, Knezl V, Okruhlicova L,et al. Myocardial gap junctions: targetsfor novel approaches in the prevention of life-threatening cardiac arrhythmias[J]. Physiol Res,2008,57Suppl2(S1-S13.
[28] Solan JL, Lampe PD. Connexin43phosphorylation: structural changes andbiological effects [J]. Biochem J,2009,419(2):261-272.
[29] Delmar M, Makita N. Cardiac connexins, mutations and arrhythmias [J]. CurrOpin Cardiol,2012,27(3):236-241.
[30] Zhang SW, Liu Y, Huang GZ,et al. Aconitine alters connexin43phosphorylation status and [Ca2+] oscillation patterns in cultured ventricularmyocytes of neonatal rats [J]. Toxicol In Vitro,2007,21(8):1476-1485.
[1] Freudenmann RW, Oxler F, Bernschneider-Reif S. The origin of MDMA(ecstasy) revisited: the true story reconstructed from the original documents [J].Addiction,2006,101(9):1241-1245.
[2] Pentney AR. An exploration of the history and controversies surroundingMDMA and MDA [J]. J Psychoactive Drugs,2001,33(3):213-221.
[3] Strote J, Lee JE, Wechsler H. Increasing MDMA use among college students:results of a national survey [J]. J Adolesc Health,2002,30(1):64-72.
[4]刘志民,周伟华,智连,et al.“摇头丸”滥用情况调查[J].中国心理卫生杂志,2000,14(5):1.
[5]卢金山,刘朝华,张锐,et al.武汉地区苯丙胺类兴奋剂滥用者的调查[J].中国药物滥用防治杂志,2008,14(1):2.
[6]刘铁桥,伟郝,王小平,et al.苯丙胺类兴奋剂(ATS)娱乐性使用情况及其人群特征[J].中国心理卫生杂志,2002,16(5):4.
[7] Carter JF, Titterton a E, Murray M,et al. Isotopic characterisation of3,4-methylenedioxyamphetamine and3,4-methylenedioxymethylamphetamine(ecstasy)[J]. Analyst,2002,127(6):830-833.
[8] Swist M, Wilamowski J, Parczewski A. Determination of synthesis method ofecstasy based on the basic impurities [J]. Forensic Sci Int,2005,152(2-3):175-184.
[9] Gimeno P, Besacier F, Bottex M,et al. A study of impurities in intermediatesand3,4-methylenedioxymethamphetamine (MDMA) samples produced viareductive amination routes [J]. Forensic Sci Int,2005,155(2-3):141-157.
[10] Puthaviriyakorn V, Siriviriyasomboon N, Phorachata J,et al. Identification ofimpurities and statistical classification of methamphetamine tablets (Ya-Ba)seized in Thailand [J]. Forensic Sci Int,2002,126(2):105-113.
[11] Gimeno P, Besacier F, Chaudron-Thozet H,et al. A contribution to thechemical profiling of3,4-methylenedioxymethamphetamine (MDMA) tablets[J]. Forensic Sci Int,2002,127(1-2):1-44.
[12] Rashed AM, Anderson RA, King LA. Solid-phase extraction for profiling ofecstasy tablets [J]. J Forensic Sci,2000,45(2):413-417.
[13] Inoue H, Kanamori T, Iwata YT,et al. Methamphetamine impurity profilingusing a0.32mm i.d. nonpolar capillary column [J]. Forensic Sci Int,2003,135(1):42-47.
[14]王虹,王军.“摇头丸”中主要成分检验[J].公安大学学报（自然科学版）,2003,33(1):3.
[15]叶青,成云飞,张祥民.摇头丸中氯胺酮和咖啡因的现场快速检测[J].化学研究与应用,2011,23(7):3.
[16] Milroy CM, Clark JC, Forrest AR. Pathology of deaths associated with"ecstasy" and "eve" misuse [J]. J Clin Pathol,1996,49(2):149-153.
[17] Baggott M, Heifets B, Jones RT,et al. Chemical analysis of ecstasy pills [J].JAMA,2000,284(17):2190.
[18] Freudenmann RW, Spitzer M. The Neuropsychopharmacology and Toxicologyof3,4-methylenedioxy-N-ethyl-amphetamine (MDEA)[J]. CNS Drug Rev,2004,10(2):89-116.
[19] Parrott AC. Is ecstasy MDMA? A review of the proportion of ecstasy tabletscontaining MDMA, their dosage levels, and the changing perceptions of purity[J]. Psychopharmacology (Berl),2004,173(3-4):234-241.
[20] Cole JC, Bailey M, Sumnall HR,et al. The content of ecstasy tablets:implications for the study of their long-term effects [J]. Addiction,2002,97(12):1531-1536.
[21]吴国萍,相秉仁.近红外光谱技术应用于摇头丸中MDMA、MA无损定量分析的研究[J].分析测试学报,2007,26(5):3.
[1] Greer G, Tolbert R. Subjective reports of the effects of MDMA in a clinicalsetting [J]. J Psychoactive Drugs,1986,18(4):319-327.
[2] Dowling GP, McDonough ET,3rd, Bost RO.'Eve' and 'Ecstasy'. A report offive deaths associated with the use of MDEA and MDMA [J]. JAMA,1987,257(12):1615-1617.
[3] Berger UV, Gu XF, Azmitia EC. The substituted amphetamines3,4-methylenedioxymethamphetamine, methamphetamine,p-chloroamphetamine and fenfluramine induce5-hydroxytryptamine releasevia a common mechanism blocked by fluoxetine and cocaine [J]. Eur JPharmacol,1992,215(2-3):153-160.
[4] Crespi D, Mennini T, Gobbi M. Carrier-dependent and Ca(2+)-dependent5-HT and dopamine release induced by (+)-amphetamine,3,4-methylendioxymethamphetamine, p-chloroamphetamine and(+)-fenfluramine [J]. Br J Pharmacol,1997,121(8):1735-1743.
[5] Han DD, Gu HH. Comparison of the monoamine transporters from human andmouse in their sensitivities to psychostimulant drugs [J]. BMC Pharmacol,2006,6(6.
[6] Vollenweider FX, Gamma A, Liechti M,et al. Psychological andcardiovascular effects and short-term sequelae of MDMA ("ecstasy") inMDMA-naive healthy volunteers [J]. Neuropsychopharmacology,1998,19(4):241-251.
[7] Cohen RS, Cocores J. Neuropsychiatric manifestations following the use of3,4-methylenedioxymethamphetamine (MDMA:"Ecstasy")[J]. ProgNeuropsychopharmacol Biol Psychiatry,1997,21(4):727-734.
[8] Kolbrich EA, Goodwin RS, Gorelick DA,et al. Physiological and subjectiveresponses to controlled oral3,4-methylenedioxymethamphetamineadministration [J]. J Clin Psychopharmacol,2008,28(4):432-440.
[9] Crean RD, Davis SA, Von Huben SN,et al. Effects of(+/-)3,4-methylenedioxymethamphetamine,(+/-)3,4-methylenedioxyamphetamine and methamphetamine on temperatureand activity in rhesus macaques [J]. Neuroscience,2006,142(2):515-525.
[10] Hall AP, Henry JA. Acute toxic effects of 'Ecstasy'(MDMA) and relatedcompounds: overview of pathophysiology and clinical management [J]. Br JAnaesth,2006,96(6):678-685.
[11] Sprague JE, Preston AS, Leifheit M,et al. Hippocampal serotonergic damageinduced by MDMA (ecstasy): effects on spatial learning [J]. Physiol Behav,2003,79(2):281-287.
[12] Badon LA, Hicks A, Lord K,et al. Changes in cardiovascular responsivenessand cardiotoxicity elicited during binge administration of Ecstasy [J]. JPharmacol Exp Ther,2002,302(3):898-907.
[13] Gesi M, Lenzi P, Soldani P,et al. Morphological effects in the mousemyocardium after methylenedioxymethamphetamine administration combinedwith loud noise exposure [J]. Anat Rec,2002,267(1):37-46.
[14] Gesi M, Soldani P, Lenzi P,et al. Ecstasy during loud noise exposure inducesdramatic ultrastructural changes in the heart [J]. Pharmacol Toxicol,2002,91(1):29-33.
[15] Mas M, Farre M, de la Torre R,et al. Cardiovascular and neuroendocrineeffects and pharmacokinetics of3,4-methylenedioxymethamphetamine inhumans [J]. J Pharmacol Exp Ther,1999,290(1):136-145.
[16] Madhok A, Boxer R, Chowdhury D. Atrial fibrillation in an adolescent--theagony of ecstasy [J]. Pediatr Emerg Care,2003,19(5):348-349.
[17] Diffley M, Armenian P, Gerona R,et al. Catecholaminergic polymorphicventricular tachycardia found in an adolescent after amethylenedioxymethamphetamine and marijuana-induced cardiac arrest [J].Crit Care Med,2012,40(7):2223-2226.
[18] Kaye S, Darke S, Duflou J. Methylenedioxymethamphetamine(MDMA)-related fatalities in Australia: demographics, circumstances,toxicology and major organ pathology [J]. Drug Alcohol Depend,2009,104(3):254-261.
[19] Yeo KK, Wijetunga M, Ito H,et al. The association of methamphetamine useand cardiomyopathy in young patients [J]. Am J Med,2007,120(2):165-171.
[20] O'Cain PA, Hletko SB, Ogden BA,et al. Cardiovascular and sympatheticresponses and reflex changes elicited by MDMA [J]. Physiol Behav,2000,70(1-2):141-148.
[21] Saez JC, Berthoud VM, Branes MC,et al. Plasma membrane channels formedby connexins: their regulation and functions [J]. Physiol Rev,2003,83(4):1359-1400.
[22] Elfgang C, Eckert R, Lichtenberg-Frate H,et al. Specific permeability andselective formation of gap junction channels in connexin-transfected HeLacells [J]. J Cell Biol,1995,129(3):805-817.
[23] Wilkins AS. Gap junction-mediated intercellular signalling in health anddisease [J]. Bioessays,1998,20(8):686-688.
[24] Dhein S. Gap junction channels in the cardiovascular system: pharmacologicaland physiological modulation [J]. Trends Pharmacol Sci,1998,19(6):229-241.
[25] Tribulova N, Knezl V, Okruhlicova L,et al. Myocardial gap junctions: targetsfor novel approaches in the prevention of life-threatening cardiac arrhythmias[J]. Physiol Res,2008,57Suppl2(S1-S13.
[26] Solan JL, Lampe PD. Connexin43phosphorylation: structural changes andbiological effects [J]. Biochem J,2009,419(2):261-272.
[27] Delmar M, Makita N. Cardiac connexins, mutations and arrhythmias [J]. CurrOpin Cardiol,2012,27(3):236-241.
[28] Cole JC, Sumnall HR. The pre-clinical behavioural pharmacology of3,4-methylenedioxymethamphetamine (MDMA)[J]. Neurosci Biobehav Rev,2003,27(3):199-217.
[29] Green AR, Mechan AO, Elliott JM,et al. The pharmacology and clinicalpharmacology of3,4-methylenedioxymethamphetamine (MDMA,"ecstasy")[J]. Pharmacol Rev,2003,55(3):463-508.
[30] Schifano F. A bitter pill. Overview of ecstasy (MDMA, MDA) relatedfatalities [J]. Psychopharmacology (Berl),2004,173(3-4):242-248.
[31] White CR, Seymour RS. Allometric scaling of mammalian metabolism [J]. JExp Biol,2005,208(Pt9):1611-1619.
[32] Winneke G, Lilienthal H. Extrapolation from animals to humans: scientificand regulatory aspects [J]. Toxicol Lett,1992,64-65Spec No(239-246.
[33] Baumann MH, Clark RD, Budzynski AG,et al. N-substituted piperazinesabused by humans mimic the molecular mechanism of3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy')[J].Neuropsychopharmacology,2005,30(3):550-560.
[34] Glennon RA, Higgs R. Investigation of MDMA-related agents in rats trainedto discriminate MDMA from saline [J]. Pharmacol Biochem Behav,1992,43(3):759-763.
[35] Oberlender R, Nichols DE. Drug discrimination studies with MDMA andamphetamine [J]. Psychopharmacology (Berl),1988,95(1):71-76.
[36] Poland RE, Lutchmansingh P, McCracken JT,et al. Abnormal ACTH andprolactin responses to fenfluramine in rats exposed to single and multipledoses of MDMA [J]. Psychopharmacology (Berl),1997,131(4):411-419.
[37] Baumann MH, Rothman RB. Neural and cardiac toxicities associated with3,4-methylenedioxymethamphetamine (MDMA)[J]. Int Rev Neurobiol,2009,88(257-296.
[38] Islam MN, Kuroki H, Hongcheng B,et al. Cardiac lesions and theirreversibility after long term administration of methamphetamine [J]. ForensicSci Int,1995,75(1):29-43.
[39] He SY, Matoba R, Fujitani N,et al. Cardiac muscle lesions associated withchronic administration of methamphetamine in rats [J]. Am J Forensic MedPathol,1996,17(2):155-162.
[40] Maeno Y, Iwasa M, Inoue H,et al. Direct effects of methamphetamine onhypertrophy and microtubules in cultured adult rat ventricular myocytes [J].Forensic Sci Int,2000,113(1-3):239-243.
[41] Maeno Y, Iwasa M, Inoue H,et al. Methamphetamine induces an increase incell size and reorganization of myofibrils in cultured adult rat cardiomyocytes[J]. Int J Legal Med,2000,113(4):201-207.
[42] Cerretani D, Riezzo I, Fiaschi AI,et al. Cardiac oxidative stress determinationand myocardial morphology after a single ecstasy (MDMA) administration ina rat model [J]. Int J Legal Med,2008,122(6):461-469.
[43] Shenouda SK, Lord KC, McIlwain E,et al. Ecstasy produces left ventriculardysfunction and oxidative stress in rats [J]. Cardiovasc Res,2008,79(4):662-670.
[44] Dumont GJ, Verkes RJ. A review of acute effects of3,4-methylenedioxymethamphetamine in healthy volunteers [J]. JPsychopharmacol,2006,20(2):176-187.
[45] Outslay MG. Understanding ecstasy [J]. JAAPA,2006,19(7):42-47.
[46] Lester SJ, Baggott M, Welm S,et al. Cardiovascular effects of3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlledtrial [J]. Ann Intern Med,2000,133(12):969-973.
[47] de la Torre R, Farre M, Roset PN,et al. Pharmacology of MDMA in humans[J]. Ann N Y Acad Sci,2000,914(225-237.
[48]冯雪芳,吕剑杰,张铁营,et al.苯丙胺类兴奋剂急性中毒65例临床分析[J].实用医学杂志,2010,26(18):2.
[49]邱泽武,孙成文,蓝红,et al.苯丙胺类兴奋剂急性中毒12例临床分析[J].中华内科杂志,2002,41(11):2.
[50] Olgar S, Dindar A, Ertugrul T,et al. Electrocardiographic andechocardiographic findings in street children known to be substance abusers[J]. Cardiol Young,2008,18(1):58-61.
[51] Beardslee MA, Lerner DL, Tadros PN,et al. Dephosphorylation andintracellular redistribution of ventricular connexin43during electricaluncoupling induced by ischemia [J]. Circ Res,2000,87(8):656-662.
[52] Joyner RW. Effects of the discrete pattern of electrical coupling onpropagation through an electrical syncytium [J]. Circ Res,1982,50(2):192-200.
[53] Spach MS, Heidlage JF. The stochastic nature of cardiac propagation at amicroscopic level. Electrical description of myocardial architecture and itsapplication to conduction [J]. Circ Res,1995,76(3):366-380.
[54] Neri M, Bello S, Bonsignore A,et al. Myocardial expression of TNF-alpha,IL-1beta, IL-6, IL-8, IL-10and MCP-1after a single MDMA doseadministered in a rat model [J]. Curr Pharm Biotechnol,2010,11(5):413-420.
[55] Fernandez-Cobo M, Gingalewski C, Drujan D,et al. Downregulation ofconnexin43gene expression in rat heart during inflammation. The role oftumour necrosis factor [J]. Cytokine,1999,11(3):216-224.
[56]赵苳,曹家琪,刘志民,et al. MDMA研究进展[J].中国药物依赖性杂志,2001,10(3):1.
[1] Bolton JL, Trush MA, Penning TM,et al. Role of quinones in toxicology [J].Chem Res Toxicol,2000,13(3):135-160.
[2] Carvalho M, Remiao F, Milhazes N,et al. Metabolism is required for theexpression of ecstasy-induced cardiotoxicity in vitro [J]. Chem Res Toxicol,2004,17(5):623-632.
[3] Carvalho M, Hawksworth G, Milhazes N,et al. Role of metabolites in MDMA(ecstasy)-induced nephrotoxicity: an in vitro study using rat and human renalproximal tubular cells [J]. Arch Toxicol,2002,76(10):581-588.
[4] Shenouda SK, Varner KJ, Carvalho F,et al. Metabolites of MDMA induceoxidative stress and contractile dysfunction in adult rat left ventricularmyocytes [J]. Cardiovasc Toxicol,2009,9(1):30-38.
[5] Carvalho M, Remiao F, Milhazes N,et al. The toxicity ofN-methyl-alpha-methyldopamine to freshly isolated rat hepatocytes isprevented by ascorbic acid and N-acetylcysteine [J]. Toxicology,2004,200(2-3):193-203.
[6] Yamashita N, Nishida M, Hoshida S,et al. Induction of manganese superoxidedismutase in rat cardiac myocytes increases tolerance to hypoxia24hoursafter preconditioning [J]. J Clin Invest,1994,94(6):2193-2199.
[7] Estevez MD, Wolf A, Schramm U. Effect of PSC833, verapamil andamiodarone on adriamycin toxicity in cultured rat cardiomyocytes [J]. ToxicolIn Vitro,2000,14(1):17-23.
[8] Nishio M, Ruch SW, Kelly JE,et al. Ouabain increases sarcoplasmic reticulumcalcium release in cardiac myocytes [J]. J Pharmacol Exp Ther,2004,308(3):1181-1190.
[9] Kimes BW, Brandt BL. Properties of a clonal muscle cell line from rat heart[J]. Exp Cell Res,1976,98(2):367-381.
[10] Hescheler J, Meyer R, Plant S,et al. Morphological, biochemical, andelectrophysiological characterization of a clonal cell (H9c2) line from rat heart[J]. Circ Res,1991,69(6):1476-1486.
[11] Sipido KR, Marban E. L-type calcium channels, potassium channels, andnovel nonspecific cation channels in a clonal muscle cell line derived fromembryonic rat ventricle [J]. Circ Res,1991,69(6):1487-1499.
[12] Zimmermann WH, Schneiderbanger K, Schubert P,et al. Tissue engineering ofa differentiated cardiac muscle construct [J]. Circ Res,2002,90(2):223-230.
[13] Blondel B, Roijen I, Cheneval JP. Heart cells in culture: a simple method forincreasing the proportion of myoblasts [J]. Experientia,1971,27(3):356-358.
[14] Brooks G, Poolman RA, McGill CJ,et al. Expression and activities of cyclinsand cyclin-dependent kinases in developing rat ventricular myocytes [J]. J MolCell Cardiol,1997,29(8):2261-2271.
[15] Simpson P, Savion S. Differentiation of rat myocytes in single cell cultureswith and without proliferating nonmyocardial cells. Cross-striations,ultrastructure, and chronotropic response to isoproterenol [J]. Circ Res,1982,50(1):101-116.
[16] de la Torre R, Farre M, Roset PN,et al. Human pharmacology of MDMA:pharmacokinetics, metabolism, and disposition [J]. Ther Drug Monit,2004,26(2):137-144.
[17] Verheyden SL, Henry JA, Curran HV. Acute, sub-acute and long-termsubjective consequences of 'ecstasy'(MDMA) consumption in430regularusers [J]. Hum Psychopharmacol,2003,18(7):507-517.
[18] Elliott SP. MDMA and MDA concentrations in antemortem and postmortemspecimens in fatalities following hospital admission [J]. J Anal Toxicol,2005,29(5):296-300.
[19] Zhang B, Green JV, Murthy SK,et al. Label-free enrichment of functionalcardiomyocytes using microfluidic deterministic lateral flow displacement [J].PLoS One,2012,7(5): e37619.
[20] Yuan Ye K, Sullivan KE, Black LD. Encapsulation of cardiomyocytes in afibrin hydrogel for cardiac tissue engineering [J]. J Vis Exp,2011,55).
[21] Jang J, Ku SY, Kim JE,et al. Notch inhibition promotes human embryonicstem cell-derived cardiac mesoderm differentiation [J]. Stem Cells,2008,26(11):2782-2790.
[22] LaFramboise WA, Scalise D, Stoodley P,et al. Cardiac fibroblasts influencecardiomyocyte phenotype in vitro [J]. Am J Physiol Cell Physiol,2007,292(5):C1799-1808.
[23] Entcheva E, Bien H, Yin L,et al. Functional cardiac cell constructs oncellulose-based scaffolding [J]. Biomaterials,2004,25(26):5753-5762.
[24] Chen HH, Mullett SJ, Stewart AF. Vgl-4, a novel member of the vestigial-likefamily of transcription cofactors, regulates alpha1-adrenergic activation ofgene expression in cardiac myocytes [J]. J Biol Chem,2004,279(29):30800-30806.
[25] Tamamori-Adachi M, Hayashida K, Nobori K,et al. Down-regulation ofp27Kip1promotes cell proliferation of rat neonatal cardiomyocytes inducedby nuclear expression of cyclin D1and CDK4. Evidence for impairedSkp2-dependent degradation of p27in terminal differentiation [J]. J BiolChem,2004,279(48):50429-50436.
[26] Tamamori-Adachi M, Ito H, Sumrejkanchanakij P,et al. Critical role of cyclinD1nuclear import in cardiomyocyte proliferation [J]. Circ Res,2003,92(1):e12-19.
[27] Arutunyan A, Webster DR, Swift LM,et al. Localized injury in cardiomyocytenetwork: a new experimental model of ischemia-reperfusion arrhythmias [J].Am J Physiol Heart Circ Physiol,2001,280(4): H1905-1915.
[28] Bueno OF, De Windt LJ, Tymitz KM,et al. The MEK1-ERK1/2signalingpathway promotes compensated cardiac hypertrophy in transgenic mice [J].EMBO J,2000,19(23):6341-6350.
[29] Nemec J, Wickman K, Clapham DE. Gbetagamma binding increases the opentime of IKACh: kinetic evidence for multiple Gbetagamma binding sites [J].Biophys J,1999,76(1Pt1):246-252.
[30] Adderley SR, Fitzgerald DJ. Oxidative damage of cardiomyocytes is limitedby extracellular regulated kinases1/2-mediated induction of cyclooxygenase-2[J]. J Biol Chem,1999,274(8):5038-5046.
[31] Reinecke H, Zhang M, Bartosek T,et al. Survival, integration, anddifferentiation of cardiomyocyte grafts: a study in normal and injured rathearts [J]. Circulation,1999,100(2):193-202.
[32] VanWinkle WB, Snuggs MB, Buja LM. Cardiogel: a biosynthetic extracellularmatrix for cardiomyocyte culture [J]. In Vitro Cell Dev Biol Anim,1996,32(8):478-485.
[33] Li RK, Mickle DA, Weisel RD,et al. In vivo survival and function oftransplanted rat cardiomyocytes [J]. Circ Res,1996,78(2):283-288.
[34] Marino TA, Walter RA, Cobb E,et al. Effects of norepinephrine on neonatalrat cardiocyte growth and differentiation [J]. In Vitro Cell Dev Biol,1990,26(3Pt1):229-236.
[35] Toraason M, Luken ME, Breitenstein M,et al. Comparative toxicity ofallylamine and acrolein in cultured myocytes and fibroblasts from neonatal ratheart [J]. Toxicology,1989,56(1):107-117.
[36] Grynberg A, Degois M, Guenot L,et al. Primary rat cardiac cell culture: diet ofthe mother rats as a determinant parameter of cardiomyoblast production fromneonates [J]. Biol Cell,1986,57(1):89-91.
[37] Jongsma HJ, Wilders R. Gap junctions in cardiovascular disease [J]. Circ Res,2000,86(12):1193-1197.
[38] Fontes MS, van Veen TA, de Bakker JM,et al. Functional consequences ofabnormal Cx43expression in the heart [J]. Biochim Biophys Acta,2012,1818(8):2020-2029.
[39] Kumar NM, Gilula NB. The gap junction communication channel [J]. Cell,1996,84(3):381-388.
[40] Saez JC, Berthoud VM, Branes MC,et al. Plasma membrane channels formedby connexins: their regulation and functions [J]. Physiol Rev,2003,83(4):1359-1400.
[41] Sohl G, Willecke K. Gap junctions and the connexin protein family [J].Cardiovasc Res,2004,62(2):228-232.
[42] Zeevi-Levin N, Barac YD, Reisner Y,et al. Gap junctional remodeling byhypoxia in cultured neonatal rat ventricular myocytes [J]. Cardiovasc Res,2005,66(1):64-73.
[43] Gourdie RG, Green CR, Severs NJ,et al. Immunolabelling patterns of gapjunction connexins in the developing and mature rat heart [J]. Anat Embryol(Berl),1992,185(4):363-378.
[44] Kwak BR, van Kempen MJ, Theveniau-Ruissy M,et al. Connexin expressionin cultured neonatal rat myocytes reflects the pattern of the intact ventricle [J].Cardiovasc Res,1999,44(2):370-380.
[45] Thiriet N, Ladenheim B, McCoy MT,et al. Analysis of ecstasy(MDMA)-induced transcriptional responses in the rat cortex [J]. FASEB J,2002,16(14):1887-1894.
[46] Tiangco DA, Lattanzio FA, Jr., Osgood CJ,et al.3,4-Methylenedioxymethamphetamine activates nuclear factor-kappaB,increases intracellular calcium, and modulates gene transcription in rat heartcells [J]. Cardiovasc Toxicol,2005,5(3):301-310.
[47] Alonso F, Krattinger N, Mazzolai L,et al. An angiotensin II-andNF-B-dependent mechanism increases connexin43in murine arteriestargeted by renin-dependent hypertension [J]. Cardiovascular Research,2010,87(1):166-176.
[48] Tornatore L, Thotakura AK, Bennett J,et al. The nuclear factor kappa Bsignaling pathway: integrating metabolism with inflammation [J]. Trends CellBiol,2012,22(11):557-566.
[49] Fernandez-Cobo M, Gingalewski C, Drujan D,et al. Downregulation ofconnexin43gene expression in rat heart during inflammation. The role oftumour necrosis factor [J]. Cytokine,1999,11(3):216-224.
[50] Gumbiner BM. Regulation of cadherin-mediated adhesion in morphogenesis[J]. Nat Rev Mol Cell Biol,2005,6(8):622-634.
[51] Angst BD, Khan LU, Severs NJ,et al. Dissociated spatial patterning of gapjunctions and cell adhesion junctions during postnatal differentiation ofventricular myocardium [J]. Circ Res,1997,80(1):88-94.
[52] Hertig CM, Butz S, Koch S,et al. N-cadherin in adult rat cardiomyocytes inculture. II. Spatio-temporal appearance of proteins involved in cell-cell contactand communication. Formation of two distinct N-cadherin/catenin complexes[J]. J Cell Sci,1996,109(Pt1)(11-20.
[53] Shaw RM, Fay AJ, Puthenveedu MA,et al. Microtubule plus-end-trackingproteins target gap junctions directly from the cell interior to adherensjunctions [J]. Cell,2007,128(3):547-560.
[54] Wei CJ, Francis R, Xu X,et al. Connexin43associated with anN-cadherin-containing multiprotein complex is required for gap junctionformation in NIH3T3cells [J]. J Biol Chem,2005,280(20):19925-19936.
[55] Li J, Patel VV, Kostetskii I,et al. Cardiac-specific loss of N-cadherin leads toalteration in connexins with conduction slowing and arrhythmogenesis [J].Circ Res,2005,97(5):474-481.
[56] Solan JL, Lampe PD. Connexin43phosphorylation: structural changes andbiological effects [J]. Biochem J,2009,419(2):261-272.
[57] Lampe PD, Lau AF. The effects of connexin phosphorylation on gapjunctional communication [J]. Int J Biochem Cell Biol,2004,36(7):1171-1186.
[58] Laird DW, Puranam KL, Revel JP. Turnover and phosphorylation dynamics ofconnexin43gap junction protein in cultured cardiac myocytes [J]. Biochem J,1991,273(Pt1)(67-72.
[59] Beardslee MA, Laing JG, Beyer EC,et al. Rapid turnover of connexin43in theadult rat heart [J]. Circ Res,1998,83(6):629-635.
[60] VanSlyke JK, Deschenes SM, Musil LS. Intracellular transport, assembly, anddegradation of wild-type and disease-linked mutant gap junction proteins [J].Mol Biol Cell,2000,11(6):1933-1946.
[61] Harris AL. Emerging issues of connexin channels: biophysics fills the gap [J].Q Rev Biophys,2001,34(3):325-472.
[1] Urschel S, Hoher T, Schubert T,et al. Protein kinase A-mediatedphosphorylation of connexin36in mouse retina results in decreased gapjunctional communication between AII amacrine cells [J]. J Biol Chem,2006,281(44):33163-33171.
[2] Lampe PD, Lau AF. Regulation of gap junctions by phosphorylation ofconnexins [J]. Arch Biochem Biophys,2000,384(2):205-215.
[3] Warn-Cramer BJ, Kurata WE, Lau AF. Biochemical analysis of connexinphosphorylation [J]. Methods Mol Biol,2001,154(431-446.
[4] Lampe PD, Lau AF. The effects of connexin phosphorylation on gapjunctional communication [J]. Int J Biochem Cell Biol,2004,36(7):1171-1186.
[5] Yogo K, Ogawa T, Akiyama M,et al. PKA implicated in the phosphorylationof Cx43induced by stimulation with FSH in rat granulosa cells [J]. J ReprodDev,2006,52(3):321-328.
[6] Berthoud VM, Ledbetter ML, Hertzberg EL,et al. Connexin43in MDCK cells:regulation by a tumor-promoting phorbol ester and Ca2+[J]. Eur J Cell Biol,1992,57(1):40-50.
[7] Reynhout JK, Lampe PD, Johnson RG. An activator of protein kinase Cinhibits gap junction communication between cultured bovine lens cells [J].Exp Cell Res,1992,198(2):337-342.
[8] Kanemitsu MY, Jiang W, Eckhart W. Cdc2-mediated phosphorylation of thegap junction protein, connexin43, during mitosis [J]. Cell Growth Differ,1998,9(1):13-21.
[9] Lampe PD, Kurata WE, Warn-Cramer BJ,et al. Formation of a distinctconnexin43phosphoisoform in mitotic cells is dependent upon p34cdc2kinase[J]. J Cell Sci,1998,111(Pt6)(833-841.
[10] Cooper CD, Lampe PD. Casein kinase1regulates connexin-43gap junctionassembly [J]. J Biol Chem,2002,277(47):44962-44968.
[11] Warn-Cramer BJ, Cottrell GT, Burt JM,et al. Regulation of connexin-43gapjunctional intercellular communication by mitogen-activated protein kinase [J].J Biol Chem,1998,273(15):9188-9196.
[12] Cameron SJ, Malik S, Akaike M,et al. Regulation of epidermal growthfactor-induced connexin43gap junction communication by bigmitogen-activated protein kinase1/ERK5but not ERK1/2kinase activation [J].J Biol Chem,2003,278(20):18682-18688.
[13] Loo LW, Berestecky JM, Kanemitsu MY,et al. pp60src-mediatedphosphorylation of connexin43, a gap junction protein [J]. J Biol Chem,1995,270(21):12751-12761.
[14] Swenson KI, Piwnica-Worms H, McNamee H,et al. Tyrosine phosphorylationof the gap junction protein connexin43is required for the pp60v-src-inducedinhibition of communication [J]. Cell Regul,1990,1(13):989-1002.
[15] Ek-Vitorin JF, King TJ, Heyman NS,et al. Selectivity of connexin43channelsis regulated through protein kinase C-dependent phosphorylation [J]. Circ Res,2006,98(12):1498-1505.
[16] Zhang SW, Liu Y, Huang GZ,et al. Aconitine alters connexin43phosphorylation status and [Ca2+] oscillation patterns in cultured ventricularmyocytes of neonatal rats [J]. Toxicol In Vitro,2007,21(8):1476-1485.
[17] Hund TJ, Lerner DL, Yamada KA,et al. Protein kinase Cepsilon mediatessalutary effects on electrical coupling induced by ischemic preconditioning [J].Heart Rhythm,2007,4(9):1183-1193.
[18] Guggilam A, Hutchinson KR, West TA,et al. In vivo and in vitro cardiacresponses to beta-adrenergic stimulation in volume-overload heart failure [J]. JMol Cell Cardiol,2013,57(47-58.
[19] O'Quinn MP, Palatinus JA, Harris BS,et al. A peptide mimetic of theconnexin43carboxyl terminus reduces gap junction remodeling and inducedarrhythmia following ventricular injury [J]. Circ Res,2011,108(6):704-715.
[20] Saez JC, Nairn AC, Czernik AJ,et al. Phosphorylation of connexin43and theregulation of neonatal rat cardiac myocyte gap junctions [J]. J Mol CellCardiol,1997,29(8):2131-2145.
[21] Brissette JL, Kumar NM, Gilula NB,et al. The tumor promoter12-O-tetradecanoylphorbol-13-acetate and the ras oncogene modulateexpression and phosphorylation of gap junction proteins [J]. Mol Cell Biol,1991,11(10):5364-5371.
[22] Lampe PD. Analyzing phorbol ester effects on gap junctional communication:a dramatic inhibition of assembly [J]. J Cell Biol,1994,127(6Pt2):1895-1905.
[23] Kwak BR, van Veen TA, Analbers LJ,et al. TPA increases conductance butdecreases permeability in neonatal rat cardiomyocyte gap junction channels [J].Exp Cell Res,1995,220(2):456-463.
[24] Mellor H, Parker PJ. The extended protein kinase C superfamily [J]. BiochemJ,1998,332(Pt2)(281-292.
[25] Nishizuka Y. Protein kinase C and lipid signaling for sustained cellularresponses [J]. FASEB J,1995,9(7):484-496.
[26] Liang JY, Wang SM, Chung TH,et al. Effects of18-glycyrrhetinic acid onserine368phosphorylation of connexin43in rat neonatal cardiomyocytes [J].Cell Biol Int,2008,32(11):1371-1379.
[27] Palatinus JA, Rhett JM, Gourdie RG. Enhanced PKCepsilon mediatedphosphorylation of connexin43at serine368by a carboxyl-terminal mimeticpeptide is dependent on injury [J]. Channels (Austin),2011,5(3):236-240.
[28] Harberd N, Artavanis-Tsakonas S, Berridge MJ,et al. Cell communication. In:Alberts B, Johnson A, Lewis J, et al.(eds). Molecular Biology of the Cell NewYork Garland Science,2002:831-906.
[29] Dempsey EC, Newton AC, Mochly-Rosen D,et al. Protein kinase C isozymesand the regulation of diverse cell responses [J]. Am J Physiol Lung Cell MolPhysiol,2000,279(3): L429-438.
[30] Melloni E, Pontremoli S, Michetti M,et al. Binding of protein kinase C toneutrophil membranes in the presence of Ca2+and its activation by aCa2+-requiring proteinase [J]. Proc Natl Acad Sci U S A,1985,82(19):6435-6439.
[31] Garcia-Rates S, Camarasa J, Sanchez-Garcia AI,et al. The effects of3,4-methylenedioxymethamphetamine (MDMA) on nicotinic receptors:intracellular calcium increase, calpain/caspase3activation, and functionalupregulation [J]. Toxicol Appl Pharmacol,2010,244(3):344-353.
[32] Beitia G, Cobreros A, Sainz L,et al.3,4-Methylenedioxymethamphetamine(ecstasy)-induced hepatotoxicity: effect on cytosolic calcium signals inisolated hepatocytes [J]. Liver,1999,19(3):234-241.
[33] Azmitia EC, Murphy RB, Whitaker-Azmitia PM. MDMA (ecstasy) effects oncultured serotonergic neurons: evidence for Ca2(+)-dependent toxicity linkedto release [J]. Brain Res,1990,510(1):97-103.
[34] Shenouda SK, Varner KJ, Carvalho F,et al. Metabolites of MDMA induceoxidative stress and contractile dysfunction in adult rat left ventricularmyocytes [J]. Cardiovasc Toxicol,2009,9(1):30-38.
[35] Tiangco DA, Lattanzio FA, Jr., Osgood CJ,et al.3,4-Methylenedioxymethamphetamine activates nuclear factor-kappaB,increases intracellular calcium, and modulates gene transcription in rat heartcells [J]. Cardiovasc Toxicol,2005,5(3):301-310.
[36] Cerretani D, Riezzo I, Fiaschi AI,et al. Cardiac oxidative stress determinationand myocardial morphology after a single ecstasy (MDMA) administration ina rat model [J]. Int J Legal Med,2008,122(6):461-469.
[37] Li C, Meng Q, Yu X,et al. Regulatory effect of connexin43on basal Ca2+signaling in rat ventricular myocytes [J]. PLoS One,2012,7(4): e36165.
[1]孙毅,徐本树,王志强,et al.250例苯丙胺类摇头丸（MDMA）滥用人群分析[J].中国药物滥用防治杂志,2004,10(5):3.
[2]郑少攀,卢延旭.苯丙胺类兴奋剂的法医毒理学研究进展[J].中国法医学杂志,2004,19(1):2.
[3] Green AR, Cross AJ, Goodwin GM. Review of the pharmacology and clinicalpharmacology of3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy")[J]. Psychopharmacology (Berl),1995,119(3):247-260.
[4] Kalant H. The pharmacology and toxicology of "ecstasy"(MDMA) andrelated drugs [J]. CMAJ,2001,165(7):917-928.
[5] Lester SJ, Baggott M, Welm S,et al. Cardiovascular effects of3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlledtrial [J]. Ann Intern Med,2000,133(12):969-973.
[6] Badon LA, Hicks A, Lord K,et al. Changes in cardiovascular responsivenessand cardiotoxicity elicited during binge administration of Ecstasy [J]. JPharmacol Exp Ther,2002,302(3):898-907.
[7] Hysek CM, Brugger R, Simmler LD,et al. Effects of the alpha(2)-adrenergicagonist clonidine on the pharmacodynamics and pharmacokinetics of3,4-methylenedioxymethamphetamine in healthy volunteers [J]. J PharmacolExp Ther,2012,340(2):286-294.
[8] Fitzgerald JL, Reid JJ. Sympathomimetic actions ofmethylenedioxymethamphetamine in rat and rabbit isolated cardiovasculartissues [J]. J Pharm Pharmacol,1994,46(10):826-832.
[9] Olgar S, Dindar A, Ertugrul T,et al. Electrocardiographic andechocardiographic findings in street children known to be substance abusers[J]. Cardiol Young,2008,18(1):58-61.
[10] Yeo KK, Wijetunga M, Ito H,et al. The association of methamphetamine useand cardiomyopathy in young patients [J]. Am J Med,2007,120(2):165-171.
[11] Mizia-Stec K, Gasior Z, Wojnicz R,et al. Severe dilated cardiomyopathy as aconsequence of Ecstasy intake [J]. Cardiovasc Pathol,2008,17(4):250-253.
[12] Dowling GP, McDonough ET,3rd, Bost RO.'Eve' and 'Ecstasy'. A report offive deaths associated with the use of MDEA and MDMA [J]. JAMA,1987,257(12):1615-1617.
[13] Gesi M, Lenzi P, Soldani P,et al. Morphological effects in the mousemyocardium after methylenedioxymethamphetamine administration combinedwith loud noise exposure [J]. Anat Rec,2002,267(1):37-46.
[14] Virmani R, Robinowitz M, Smialek JE,et al. Cardiovascular effects of cocaine:an autopsy study of40patients [J]. Am Heart J,1988,115(5):1068-1076.
[15] Gesi M, Soldani P, Lenzi P,et al. Ecstasy during loud noise exposure inducesdramatic ultrastructural changes in the heart [J]. Pharmacol Toxicol,2002,91(1):29-33.
[16] Madhok A, Boxer R, Chowdhury D. Atrial fibrillation in an adolescent--theagony of ecstasy [J]. Pediatr Emerg Care,2003,19(5):348-349.
[17] Diffley M, Armenian P, Gerona R,et al. Catecholaminergic polymorphicventricular tachycardia found in an adolescent after amethylenedioxymethamphetamine and marijuana-induced cardiac arrest [J].Crit Care Med,2012,40(7):2223-2226.
[18] Patel MM, Belson MG, Wright D,et al. Methylenedioxymethamphetamine(ecstasy)-related myocardial hypertrophy: an autopsy study [J]. Resuscitation,2005,66(2):197-202.
[19] Karch SB, Green GS, Young S. Myocardial hypertrophy and coronary arterydisease in male cocaine users [J]. J Forensic Sci,1995,40(4):591-595.
[20] Henning RJ, Silva J, Reddy V,et al. Cocaine increases beta-myosinheavy-chain protein expression in cardiac myocytes [J]. J CardiovascPharmacol Ther,2000,5(4):313-322.
[21] Karch SB, Stephens BG, Ho CH. Methamphetamine-related deaths in SanFrancisco: demographic, pathologic, and toxicologic profiles [J]. J ForensicSci,1999,44(2):359-368.
[22] Kaye S, Darke S, Duflou J. Methylenedioxymethamphetamine(MDMA)-related fatalities in Australia: demographics, circumstances,toxicology and major organ pathology [J]. Drug Alcohol Depend,2009,104(3):254-261.
[23] Wijetunga M, Seto T, Lindsay J,et al. Crystal methamphetamine-associatedcardiomyopathy: tip of the iceberg?[J]. J Toxicol Clin Toxicol,2003,41(7):981-986.
[24] Milroy CM, Clark JC, Forrest AR. Pathology of deaths associated with"ecstasy" and "eve" misuse [J]. J Clin Pathol,1996,49(2):149-153.
[25] He SY, Matoba R, Fujitani N,et al. Cardiac muscle lesions associated withchronic administration of methamphetamine in rats [J]. Am J Forensic MedPathol,1996,17(2):155-162.
[26] Maeno Y, Iwasa M, Inoue H,et al. Direct effects of methamphetamine onhypertrophy and microtubules in cultured adult rat ventricular myocytes [J].Forensic Sci Int,2000,113(1-3):239-243.
[27] Cerretani D, Riezzo I, Fiaschi AI,et al. Cardiac oxidative stress determinationand myocardial morphology after a single ecstasy (MDMA) administration ina rat model [J]. Int J Legal Med,2008,122(6):461-469.
[28] Fineschi V, Centini F, Mazzeo E,et al. Adam (MDMA) and Eve (MDEA)misuse: an immunohistochemical study on three fatal cases [J]. Forensic SciInt,1999,104(1):65-74.
[29] Maeno Y, Iwasa M, Inoue H,et al. Methamphetamine induces an increase incell size and reorganization of myofibrils in cultured adult rat cardiomyocytes[J]. Int J Legal Med,2000,113(4):201-207.
[30] Carvalho M, Remiao F, Milhazes N,et al. Metabolism is required for theexpression of ecstasy-induced cardiotoxicity in vitro [J]. Chem Res Toxicol,2004,17(5):623-632.
[31] Bexis S, Docherty JR. Effects of MDMA, MDA and MDEA on blood pressure,heart rate, locomotor activity and body temperature in the rat involvealpha-adrenoceptors [J]. Br J Pharmacol,2006,147(8):926-934.
[32] Hysek CM, Simmler LD, Ineichen M,et al. The norepinephrine transporterinhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans[J]. Clin Pharmacol Ther,2011,90(2):246-255.
[33] Mas M, Farre M, de la Torre R,et al. Cardiovascular and neuroendocrineeffects and pharmacokinetics of3,4-methylenedioxymethamphetamine inhumans [J]. J Pharmacol Exp Ther,1999,290(1):136-145.
[34] Turillazzi E, Riezzo I, Neri M,et al. MDMA toxicity and pathologicalconsequences: a review about experimental data and autopsy findings [J]. CurrPharm Biotechnol,2010,11(5):500-509.
[35] Rona G. Catecholamine cardiotoxicity [J]. J Mol Cell Cardiol,1985,17(4):291-306.
[36] Wheatley AM, Thandroyen FT, Opie LH. Catecholamine-induced myocardialcell damage: catecholamines or adrenochrome [J]. J Mol Cell Cardiol,1985,17(4):349-359.
[37] O'Cain PA, Hletko SB, Ogden BA,et al. Cardiovascular and sympatheticresponses and reflex changes elicited by MDMA [J]. Physiol Behav,2000,70(1-2):141-148.
[38] Shenouda SK, Lord KC, McIlwain E,et al. Ecstasy produces left ventriculardysfunction and oxidative stress in rats [J]. Cardiovasc Res,2008,79(4):662-670.
[39] Tiangco DA, Lattanzio FA, Jr., Osgood CJ,et al.3,4-Methylenedioxymethamphetamine activates nuclear factor-kappaB,increases intracellular calcium, and modulates gene transcription in rat heartcells [J]. Cardiovasc Toxicol,2005,5(3):301-310.
[40] Cleary L, Docherty JR. Actions of amphetamine derivatives and cathinone atthe noradrenaline transporter [J]. Eur J Pharmacol,2003,476(1-2):31-34.
[41] Schifano F, Oyefeso A, Webb L,et al. Review of deaths related to takingecstasy, England and Wales,1997-2000[J]. BMJ,2003,326(7380):80-81.
[42] McDaid J, Docherty JR. Vascular actions of MDMA involve alpha1andalpha2-adrenoceptors in the anaesthetized rat [J]. Br J Pharmacol,2001,133(3):429-437.
[43] Carvalho M, Remiao F, Milhazes N,et al. The toxicity ofN-methyl-alpha-methyldopamine to freshly isolated rat hepatocytes isprevented by ascorbic acid and N-acetylcysteine [J]. Toxicology,2004,200(2-3):193-203.
[44] Shenouda SK, Varner KJ, Carvalho F,et al. Metabolites of MDMA induceoxidative stress and contractile dysfunction in adult rat left ventricularmyocytes [J]. Cardiovasc Toxicol,2009,9(1):30-38.
[45] Neri M, Bello S, Bonsignore A,et al. Myocardial expression of TNF-alpha,IL-1beta, IL-6, IL-8, IL-10and MCP-1after a single MDMA doseadministered in a rat model [J]. Curr Pharm Biotechnol,2010,11(5):413-420.
[46] Eddahibi S, Raffestin B, Hamon M,et al. Is the serotonin transporter involvedin the pathogenesis of pulmonary hypertension?[J]. J Lab Clin Med,2002,139(4):194-201.
[47] Droogmans S, Cosyns B, D'Haenen H,et al. Possible association between3,4-methylenedioxymethamphetamine abuse and valvular heart disease [J].Am J Cardiol,2007,100(9):1442-1445.
[48] Sano R, Hasuike T, Nakano M,et al. A fatal case of myocardial damage due tomisuse of the "designer drug" MDMA [J]. Leg Med (Tokyo),2009,11(6):294-297.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |